// Auto-generated research studies data
// Generated from PubMed and scientific database research
// Total studies: 247

export interface Study {
  id: string;
  peptide: string;
  category: string;
  title: string;
  authors: string;
  year: string;
  journal: string;
  pubmedId?: string;
  url: string;
  keyFindings: string;
  evidenceLevel: string;
  citations?: number;
  fdaStatus?: string;
}

export const studies: Study[] = [
  {
    id: "s1",
    peptide: "BPC-157",
    category: "Regenerative",
    title: "Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing",
    authors: "Gwyer D, Wragg NM, Wilson SL",
    year: "2019",
    journal: "Cell and Tissue Research",
    pubmedId: "30915550",
    url: "https://pubmed.ncbi.nlm.nih.gov/30915550/",
    keyFindings: "BPC 157 has demonstrated consistently positive and prompt healing effects for various injury types, both traumatic and systemic, and for a plethora of soft tissues. It has promise as a therapy to conservatively treat or aid recovery in hypovascular and hypocellular soft tissues such as tendon and ligaments.",
    evidenceLevel: "Review",
    citations: 82,
    fdaStatus: "Investigational"
  },
  {
    id: "s2",
    peptide: "BPC-157",
    category: "Regenerative",
    title: "Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review",
    authors: "J\u00f3zwiak M, Bauer M, Kamysz W, Kleczkowska P",
    year: "2025",
    journal: "Pharmaceuticals (Basel)",
    pubmedId: "40005999",
    url: "https://pubmed.ncbi.nlm.nih.gov/40005999/",
    keyFindings: "BPC 157 has pleiotropic beneficial effects in various preclinical models, a desirable safety profile, and is not currently banned by WADA. However, it has not been approved for use in standard medicine by the FDA and other global regulatory authorities due to the absence of sufficient and comprehensive clinical studies confirming its health benefits in humans.",
    evidenceLevel: "Review",
    citations: 2,
    fdaStatus: "Research Only"
  },
  {
    id: "s3",
    peptide: "BPC-157",
    category: "Regenerative",
    title: "Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts",
    authors: "Chang CH, Tsai WC, Hsu YH, Pang JH",
    year: "2014",
    journal: "Molecules",
    pubmedId: "25415472",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/",
    keyFindings: "BPC 157 dose- and time-dependently increased the expression of growth hormone receptor in tendon fibroblasts at both the mRNA and protein levels. This upregulation may potentiate the proliferative effect of growth hormone and contribute to the healing of tendons.",
    evidenceLevel: "Preclinical",
    citations: 183,
    fdaStatus: "Research Only"
  },
  {
    id: "s4",
    peptide: "Semaglutide",
    category: "Weight Management",
    title: "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial",
    authors: "Rubino D, et al.",
    year: "2021",
    journal: "JAMA",
    pubmedId: "33755728",
    url: "https://pubmed.ncbi.nlm.nih.gov/33755728/",
    keyFindings: "Among adults with overweight or obesity who completed a 20-week run-in period with subcutaneous semaglutide, 2.4 mg, continued treatment with semaglutide compared with switching to placebo resulted in continued weight loss over the following 48 weeks.",
    evidenceLevel: "RCT",
    citations: 1394,
    fdaStatus: "FDA Approved"
  },
  {
    id: "s5",
    peptide: "Semaglutide",
    category: "Weight Management",
    title: "Semaglutide for the treatment of overweight and obesity: A review",
    authors: "Bergmann NC, et al.",
    year: "2022",
    journal: "Diabetes Obes Metab",
    pubmedId: "36254579",
    url: "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092086/",
    keyFindings: "This review of the STEP clinical trial program concludes that once-weekly subcutaneous semaglutide 2.4 mg is associated with substantial and sustained weight loss in people with overweight or obesity, accompanied by improvements in cardiometabolic risk factors.",
    evidenceLevel: "Review",
    citations: 131,
    fdaStatus: "FDA Approved"
  },
  {
    id: "s6",
    peptide: "Semaglutide",
    category: "Weight Management",
    title: "Spotlight on the Mechanism of Action of Semaglutide",
    authors: "Papakonstantinou I, et al.",
    year: "2024",
    journal: "Curr Issues Mol Biol",
    pubmedId: "39728000",
    url: "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674233/",
    keyFindings: "This review explores the molecular mechanisms of semaglutide, including its effects on appetite regulation, adipose tissue browning, and anti-inflammatory pathways, while noting that much of the evidence is from preclinical studies.",
    evidenceLevel: "Review",
    citations: 34,
    fdaStatus: "FDA Approved"
  },
  {
    id: "s7",
    peptide: "Tirzepatide",
    category: "Weight Management",
    title: "Tirzepatide Once Weekly for the Treatment of Obesity",
    authors: "Ania M. Jastreboff, M.D., Ph.D., et al.",
    year: "2022",
    journal: "The New England Journal of Medicine",
    pubmedId: "35658024",
    url: "https://www.nejm.org/doi/full/10.1056/NEJMoa2206038",
    keyFindings: "In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight.",
    evidenceLevel: "RCT",
    citations: 3485,
    fdaStatus: "FDA Approved"
  },
  {
    id: "s8",
    peptide: "Tirzepatide",
    category: "Weight Management",
    title: "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes",
    authors: "Juan P. Fr\u00edas, M.D., et al.",
    year: "2021",
    journal: "The New England Journal of Medicine",
    pubmedId: "34170647",
    url: "https://www.nejm.org/doi/full/10.1056/NEJMoa2107519",
    keyFindings: "In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks.",
    evidenceLevel: "RCT",
    citations: 2089,
    fdaStatus: "FDA Approved"
  },
  {
    id: "s9",
    peptide: "Tirzepatide",
    category: "Weight Management",
    title: "Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial",
    authors: "Julio Rosenstock, MD, et al.",
    year: "2021",
    journal: "The Lancet",
    pubmedId: "34174221",
    url: "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01324-6/fulltext",
    keyFindings: "Tirzepatide showed robust improvements in glycaemic control and bodyweight, without increased risk of hypoglycaemia.",
    evidenceLevel: "RCT",
    citations: 1162,
    fdaStatus: "FDA Approved"
  },
  {
    id: "s10",
    peptide: "Thymosin Alpha-1",
    category: "Immune Support",
    title: "Thymosin alpha 1: A comprehensive review of the literature",
    authors: "Dominari A, et al.",
    year: "2020",
    journal: "World J Virol",
    pubmedId: "33362999",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC7747025/",
    keyFindings: "Thymosin alpha 1 is a peptide that modifies, enhances, and restores immune function, and has been used in treating immunocompromised states, malignancies, and as a vaccine enhancer. It may also help improve outcomes in severely ill COVID-19 patients.",
    evidenceLevel: "Review",
    citations: 71,
    fdaStatus: "Investigational"
  },
  {
    id: "s11",
    peptide: "Thymosin Alpha-1",
    category: "Immune Support",
    title: "Thymosin alpha 1: Biological activities, applications and genetic engineering production",
    authors: "Li J, et al.",
    year: "2010",
    journal: "Peptides",
    pubmedId: "20699109",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC7115394/",
    keyFindings: "This peptide can enhance T-cell, dendritic cell (DC) and antibody responses, modulate cytokines and chemokines production and block steroid-induced apoptosis of thymocytes. Due to its pleiotropic biological activities, T\u03b11 has gained increasing interest in recent years and has been used for the treatment of various diseases in clinic.",
    evidenceLevel: "Review",
    citations: 89,
    fdaStatus: "Investigational"
  },
  {
    id: "s12",
    peptide: "Thymosin Alpha-1",
    category: "Immune Support",
    title: "Phenotypic drug discovery: a case for thymosin alpha-1",
    authors: "Garaci E, et al.",
    year: "2024",
    journal: "Front Med (Lausanne)",
    pubmedId: "38854697",
    url: "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1388959/full",
    keyFindings: "This article explores the experiences of researchers testing the effect of a thymic peptide hormone, thymosin alpha-1, in preclinical and clinical settings and discuss how its therapeutic utility in the precision medicine era can be accommodated within the PDD framework.",
    evidenceLevel: "Review",
    citations: 3,
    fdaStatus: "Investigational"
  },
  {
    id: "s13",
    peptide: "5-Amino-1MQ",
    category: "Weight Management",
    title: "Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice",
    authors: "Neelakantan H, et al.",
    year: "2018",
    journal: "Biochemical Pharmacology",
    pubmedId: "29155147",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC5826726/",
    keyFindings: "Small molecule NNMT inhibitors, including 5-amino-1MQ, reversed high-fat diet-induced obesity in mice by reducing body weight and white adipose tissue mass without altering food intake. These findings support the development of NNMT inhibitors as a potential treatment for obesity and related metabolic disorders.",
    evidenceLevel: "Preclinical",
    citations: 91,
    fdaStatus: "Investigational"
  },
  {
    id: "s14",
    peptide: "5-Amino-1MQ",
    category: "Weight Management",
    title: "Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes",
    authors: "Liu JR, et al.",
    year: "2021",
    journal: "BioMed Research International",
    pubmedId: "34368359",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC8337113/",
    keyFindings: "This review summarizes the roles of NNMT in obesity and type 2 diabetes, highlighting that NNMT inhibition increases energy expenditure, reduces body weight, and improves insulin sensitivity. The paper discusses 5-amino-1MQ as a potent and selective NNMT inhibitor with promising therapeutic potential for treating obesity and related metabolic diseases.",
    evidenceLevel: "Review",
    citations: 20,
    fdaStatus: "Investigational"
  },
  {
    id: "s15",
    peptide: "5-Amino-1MQ",
    category: "Weight Management",
    title: "Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice",
    authors: "Dimet-Wiley A, et al.",
    year: "2022",
    journal: "Scientific Reports",
    pubmedId: "35013523",
    url: "https://www.nature.com/articles/s41598-021-03670-5",
    keyFindings: "This study found that combining a low-fat diet with an NNMT inhibitor (5-amino-1MQ) in diet-induced obese mice led to significant weight loss and changes in the gut microbiome, characterized by decreased Erysipelatoclostridium and increased Lactobacillus. These findings suggest a potential role for the microbiome in the metabolic benefits of NNMT inhibition.",
    evidenceLevel: "Preclinical",
    citations: 7,
    fdaStatus: "Investigational"
  },
  {
    id: "s16",
    peptide: "Adipotide",
    category: "Weight Management",
    title: "A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys",
    authors: "Barnhart KF, et al.",
    year: "2011",
    journal: "Sci Transl Med",
    pubmedId: "22072637",
    url: "https://pubmed.ncbi.nlm.nih.gov/22072637/",
    keyFindings: "Treatment with adipotide induced targeted apoptosis within blood vessels of white adipose tissue, resulting in rapid weight loss and improved insulin resistance in obese monkeys.",
    evidenceLevel: "Preclinical",
    citations: 116,
    fdaStatus: "Investigational"
  },
  {
    id: "s17",
    peptide: "Adipotide",
    category: "Weight Management",
    title: "A First-in-Man, Phase I Evaluation of a Single Cycle of Prohibitin Targeting Peptide 1 (PROHIBITIN-TP01) in Patients With Metastatic Prostate Cancer and Obesity",
    authors: "MD Anderson Cancer Center",
    year: "2012",
    journal: "ClinicalTrials.gov",
    pubmedId: "NCT01262664",
    url: "https://clinicaltrials.gov/study/NCT01262664",
    keyFindings: "This Phase 1 trial was designed to evaluate the safety and maximum tolerated dose of Adipotide in patients with prostate cancer. The study was initiated but the results are not available on the clinicaltrials.gov page.",
    evidenceLevel: "Clinical Trial",
    fdaStatus: "Investigational"
  },
  {
    id: "s18",
    peptide: "Adipotide",
    category: "Weight Management",
    title: "Peptide Designed to Elicit Apoptosis in Adipose Tissue Endothelium Reduces Food Intake and Body Weight",
    authors: "Kim DH, et al.",
    year: "2010",
    journal: "Diabetes",
    pubmedId: "20103704",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC2844838/",
    keyFindings: "Proapoptotic peptide completely reversed high-fat diet-induced obesity in mice and reduced body weight in mice and rats on a high-fat diet by reducing food intake without causing illness.",
    evidenceLevel: "Preclinical",
    citations: 65,
    fdaStatus: "Research Only"
  },
  {
    id: "s19",
    peptide: "Alpha-GPC",
    category: "Cognitive",
    title: "Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men",
    authors: "Kerksick CM, et al.",
    year: "2024",
    journal: "Nutrients",
    pubmedId: "39683633",
    url: "https://pubmed.ncbi.nlm.nih.gov/39683633/",
    keyFindings: "A-GPC supplementation significantly increased cognitive performance in a group of young, healthy males as measured by changes in the Stroop Total Score and completion time of the Stroop test.",
    evidenceLevel: "RCT",
    citations: 6,
    fdaStatus: "Supplement"
  },
  {
    id: "s20",
    peptide: "Alpha-GPC",
    category: "Cognitive",
    title: "The Nutritional Supplement L-Alpha Glycerylphosphorylcholine Promotes Atherosclerosis",
    authors: "Wang Z, et al.",
    year: "2021",
    journal: "Int J Mol Sci",
    pubmedId: "34948275",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC8708068/",
    keyFindings: "GPC promotes atherosclerosis through multiple mechanisms and that caution should be applied when using GPC as a nutritional supplement.",
    evidenceLevel: "Preclinical",
    citations: 44,
    fdaStatus: "Supplement"
  },
  {
    id: "s21",
    peptide: "Alpha-GPC",
    category: "Cognitive",
    title: "Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial",
    authors: "De Jesus Moreno Moreno M, et al.",
    year: "2003",
    journal: "Clin Ther",
    pubmedId: "12637119",
    url: "https://pubmed.ncbi.nlm.nih.gov/12637119/",
    keyFindings: "The results of this study suggest the clinical usefulness and tolerability of CA in the treatment of the cognitive symptoms of dementia disorders of the Alzheimer type.",
    evidenceLevel: "RCT",
    citations: 266,
    fdaStatus: "Investigational"
  },
  {
    id: "s22",
    peptide: "AOD-9604",
    category: "Weight Management",
    title: "Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans",
    authors: "Heike Stier, Evert Vos, David Kenley",
    year: "2013",
    journal: "Journal of Endocrinology and Metabolism",
    pubmedId: "29127405",
    url: "https://www.jofem.org/index.php/jofem/article/view/157",
    keyFindings: "AOD9604 displayed a very good safety and tolerability profile indistinguishable from placebo. AOD9604 did not result in any of the adverse effects associated with full-length hGH treatment.",
    evidenceLevel: "Clinical Trial",
    citations: 18,
    fdaStatus: "Investigational"
  },
  {
    id: "s23",
    peptide: "AOD-9604",
    category: "Weight Management",
    title: "Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone",
    authors: "Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R.",
    year: "2000",
    journal: "Hormone Research",
    pubmedId: "11146367",
    url: "https://pubmed.ncbi.nlm.nih.gov/11146367/",
    keyFindings: "Daily treatment with an oral dose of AOD9604 of 500 microg/kg body weight for 19 days reduced over 50% body weight gain of the animals in comparison with the control. The analogue of the hGH lipolytic domain may have the potential to be developed into an orally usable and safe therapeutic agent for obesity.",
    evidenceLevel: "Preclinical",
    citations: 45,
    fdaStatus: "Investigational"
  },
  {
    id: "s24",
    peptide: "AOD-9604",
    category: "Weight Management",
    title: "Obesity drug codenamed AOD9604 highly successful in trials",
    authors: "Metabolic Pharmaceuticals Limited",
    year: "2004",
    journal: "News-Medical.net",
    pubmedId: "Not available",
    url: "https://www.news-medical.net/news/2004/12/16/6878.aspx",
    keyFindings: "AOD9604, taken orally once daily by 300 obese patients over a 12-week period, induced weight loss. The group receiving the 1mg dose lost the most weight, averaging a weight loss over the 12 weeks of 2.8 kilograms, more than triple the weight lost by those on placebo.",
    evidenceLevel: "Clinical Trial",
    fdaStatus: "Investigational"
  },
  {
    id: "s25",
    peptide: "BPC-157",
    category: "Regenerative",
    title: "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review",
    authors: "Nikhil Vasireddi et al.",
    year: "2025",
    journal: "HSS Journal",
    pubmedId: "40756949",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/",
    keyFindings: "This systematic review of level IV and level V studies suggests that BPC-157 shows promise for promoting recovery from musculoskeletal injuries. Adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety.",
    evidenceLevel: "Systematic Review",
    citations: 8,
    fdaStatus: "Investigational"
  },
  {
    id: "s26",
    peptide: "BPC-157",
    category: "Regenerative",
    title: "Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing",
    authors: "Daniel Gwyer et al.",
    year: "2019",
    journal: "Cell and Tissue Research",
    pubmedId: "30915550",
    url: "https://pubmed.ncbi.nlm.nih.gov/30915550/",
    keyFindings: "BPC 157 has demonstrated consistently positive and prompt healing effects for various injury types, both traumatic and systemic and for a plethora of soft tissues. However, to date, the majority of studies have been performed on small rodent models and the efficacy of BPC 157 is yet to be confirmed in humans.",
    evidenceLevel: "Review",
    citations: 38,
    fdaStatus: "Research Only"
  },
  {
    id: "s27",
    peptide: "BPC-157",
    category: "Regenerative",
    title: "PCO-02 - Safety and Pharmacokinetics Trial",
    authors: "PharmaCotheria d.o.o.",
    year: "2015",
    journal: "ClinicalTrials.gov",
    pubmedId: "NCT02637284",
    url: "https://clinicaltrials.gov/study/NCT02637284",
    keyFindings: "A phase I clinical trial in healthy volunteers to study the safety and pharmacokinetics of BPC-157, a pentadecapeptide from a gastric source. The study consisted of the oral administration of PCO-02 tablets containing 1mg of BPC-157 or a placebo.",
    evidenceLevel: "Clinical Trial",
    fdaStatus: "Investigational"
  },
  {
    id: "s28",
    peptide: "Cagrilintide",
    category: "Weight Management",
    title: "Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial",
    authors: "Lau DCW, et al.",
    year: "2021",
    journal: "The Lancet",
    pubmedId: "34798060",
    url: "https://pubmed.ncbi.nlm.nih.gov/34798060/",
    keyFindings: "Treatment with cagrilintide in people with overweight and obesity led to significant reductions in bodyweight and was well tolerated.",
    evidenceLevel: "RCT",
    citations: 242,
    fdaStatus: "Investigational"
  },
  {
    id: "s29",
    peptide: "Cagrilintide",
    category: "Weight Management",
    title: "Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial",
    authors: "Frias JP, et al.",
    year: "2023",
    journal: "The Lancet",
    pubmedId: "37364590",
    url: "https://pubmed.ncbi.nlm.nih.gov/37364590/",
    keyFindings: "Treatment with CagriSema resulted in significantly greater weight loss versus semaglutide and cagrilintide and was well tolerated.",
    evidenceLevel: "RCT",
    citations: 292,
    fdaStatus: "Investigational"
  },
  {
    id: "s30",
    peptide: "Cagrilintide",
    category: "Weight Management",
    title: "Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity",
    authors: "D'Ascanio AM, et al.",
    year: "2024",
    journal: "Cardiology in Review",
    pubmedId: "36883831",
    url: "https://pubmed.ncbi.nlm.nih.gov/36883831/",
    keyFindings: "Cagrilintide, a long-acting amylin analog, has shown promising weight-loss effects and is being developed in combination with semaglutide for sustained weight loss.",
    evidenceLevel: "Review",
    citations: 42,
    fdaStatus: "Investigational"
  },
  {
    id: "s31",
    peptide: "Cerebrolysin",
    category: "Neuroprotective",
    title: "Cerebrolysin: a review of its use in dementia",
    authors: "Plosker GL, Gauthier S",
    year: "2009",
    journal: "Drugs & Aging",
    pubmedId: "19848437",
    url: "https://pubmed.ncbi.nlm.nih.gov/19848437/",
    keyFindings: "Cerebrolysin was superior to placebo in improving global outcome measures and cognitive ability in patients with Alzheimer's disease. It also showed beneficial effects in patients with vascular dementia.",
    evidenceLevel: "Review",
    citations: 127,
    fdaStatus: "Investigational"
  },
  {
    id: "s32",
    peptide: "Cerebrolysin",
    category: "Neuroprotective",
    title: "Cerebrolysin for acute ischaemic stroke",
    authors: "Ziganshina LE, et al.",
    year: "2023",
    journal: "Cochrane Database of Systematic Reviews",
    pubmedId: "37818602",
    url: "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007026.pub7/abstract",
    keyFindings: "This Cochrane review found no evidence of a beneficial effect of Cerebrolysin on key clinical outcomes in acute ischemic stroke and noted a potential increase in non-fatal serious adverse events.",
    evidenceLevel: "Meta-Analysis",
    citations: 212,
    fdaStatus: "Investigational"
  },
  {
    id: "s33",
    peptide: "Cerebrolysin",
    category: "Neuroprotective",
    title: "Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials",
    authors: "Bornstein NM, et al.",
    year: "2018",
    journal: "Neurological Sciences",
    pubmedId: "29248999",
    url: "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884916/",
    keyFindings: "This meta-analysis of nine randomized controlled trials confirmed that Cerebrolysin has a beneficial effect on early global neurological deficits in patients with acute ischemic stroke, with a safety profile comparable to placebo.",
    evidenceLevel: "Meta-Analysis",
    citations: 120,
    fdaStatus: "Investigational"
  },
  {
    id: "s34",
    peptide: "CJC-1295",
    category: "Growth Hormone",
    title: "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults",
    authors: "Teichman SL, et al.",
    year: "2006",
    journal: "J Clin Endocrinol Metab",
    pubmedId: "16352683",
    url: "https://pubmed.ncbi.nlm.nih.gov/16352683/",
    keyFindings: "Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated. There was evidence of a cumulative effect after multiple doses.",
    evidenceLevel: "Randomized Controlled Trial",
    citations: 100,
    fdaStatus: "Investigational"
  },
  {
    id: "s35",
    peptide: "CJC-1295",
    category: "Growth Hormone",
    title: "Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects",
    authors: "Sackmann-Sala L, et al.",
    year: "2009",
    journal: "Growth Horm IGF Res",
    pubmedId: "19386527",
    url: "https://pubmed.ncbi.nlm.nih.gov/19386527/",
    keyFindings: "CJC-1295 treatment led to changes in serum proteins, including apolipoprotein A1, transthyretin, beta-hemoglobin, and albumin fragments. These proteins are potential biomarkers for GH and IGF-1 action.",
    evidenceLevel: "Clinical Trial",
    citations: 46,
    fdaStatus: "Investigational"
  },
  {
    id: "s36",
    peptide: "CJC-1295",
    category: "Growth Hormone",
    title: "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog",
    authors: "Ionescu M, et al.",
    year: "2006",
    journal: "J Clin Endocrinol Metab",
    pubmedId: "17018654",
    url: "https://pubmed.ncbi.nlm.nih.gov/17018654/",
    keyFindings: "CJC-1295 increased trough and mean GH secretion and IGF-I production with preserved GH pulsatility. The marked enhancement of trough GH levels by continuous GHRH stimulation implicates the importance of this effect on increasing IGF-I.",
    evidenceLevel: "Clinical Trial",
    citations: 50,
    fdaStatus: "Investigational"
  },
  {
    id: "s37",
    peptide: "Cortexin",
    category: "Neuroprotective",
    title: "[Cortexin. Molecular mechanisms and targets of neuroprotective activity]",
    authors: "Gomazkov OA",
    year: "2015",
    journal: "Zh Nevrol Psikhiatr Im S S Korsakova",
    pubmedId: "26356623",
    url: "https://pubmed.ncbi.nlm.nih.gov/26356623/",
    keyFindings: "Cortexin, a neuropeptide drug, has a range of targets for correcting molecular and cellular processes in pathological conditions. Its components provide a new perspective on neuroprotection mechanisms.",
    evidenceLevel: "Review",
    fdaStatus: "Investigational"
  },
  {
    id: "s38",
    peptide: "Cortexin",
    category: "Neuroprotective",
    title: "Neurotropic Effects of Cortexin on Models of Mental and Physical Developmental Delay",
    authors: "Kurkin DV et al.",
    year: "2025",
    journal: "Biomedicines",
    pubmedId: "40299434",
    url: "https://pubmed.ncbi.nlm.nih.gov/40299434/",
    keyFindings: "Cortexin, administered either intramuscularly or rectally, showed neurotropic effects in rat models of developmental delays. It reduced neurological deficits, improved motor activity, and decreased structural brain changes.",
    evidenceLevel: "Preclinical",
    fdaStatus: "Investigational"
  },
  {
    id: "s39",
    peptide: "Cortexin",
    category: "Neuroprotective",
    title: "[Molecular mechanisms of brain peptide-containing drugs: cortexin]",
    authors: "Gulyaeva NV",
    year: "2018",
    journal: "Zh Nevrol Psikhiatr Im S S Korsakova",
    pubmedId: "30499504",
    url: "https://pubmed.ncbi.nlm.nih.gov/30499504/",
    keyFindings: "Cortexin demonstrated anti-inflammatory and antioxidant effects in a rat model of accelerated aging. It also inhibited brain caspase-8, suggesting its neuroprotective effects are linked to key processes in neuroplasticity.",
    evidenceLevel: "Preclinical",
    fdaStatus: "Investigational"
  },
  {
    id: "s40",
    peptide: "Dihexa",
    category: "Cognitive",
    title: "AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway",
    authors: "Sun X, et al.",
    year: "2021",
    journal: "Brain Sciences",
    pubmedId: "34827483",
    url: "https://www.mdpi.com/2076-3425/11/11/1487",
    keyFindings: "Dihexa restored spatial learning and cognitive functions, increased neuronal cells, and reduced inflammation in a mouse model of Alzheimer's disease.",
    evidenceLevel: "Preclinical",
    citations: 9,
    fdaStatus: "Research Only"
  },
  {
    id: "s41",
    peptide: "Dihexa",
    category: "Cognitive",
    title: "Stem cell, Granulocyte-Colony Stimulating Factor and/or Dihexa to promote limb function recovery in a rat sciatic nerve damage-repair model: Experimental animal studies",
    authors: "Weiss JB, et al.",
    year: "2021",
    journal: "Annals of Medicine and Surgery",
    pubmedId: "34765139",
    url: "https://www.sciencedirect.com/science/article/pii/S2049080121008670",
    keyFindings: "Dihexa, in combination with mesenchymal stem cells, improved motor function recovery and reduced foot flexion contractures in a rat model of sciatic nerve injury.",
    evidenceLevel: "Preclinical",
    citations: 2,
    fdaStatus: "Research Only"
  },
  {
    id: "s42",
    peptide: "Dihexa",
    category: "Cognitive",
    title: "Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents",
    authors: "McCoy AT, et al.",
    year: "2013",
    journal: "The Journal of Pharmacology and Experimental Therapeutics",
    pubmedId: "23065934",
    url: "https://www.sciencedirect.com/science/article/abs/pii/S002235652418473X",
    keyFindings: "Dihexa, a metabolically stabilized analog of angiotensin IV, shows significant anti-dementia and synaptogenic activity in rat models, suggesting its potential as a therapeutic for cognitive disorders like Alzheimer's disease.",
    evidenceLevel: "Preclinical",
    citations: 64,
    fdaStatus: "Research Only"
  },
  {
    id: "s43",
    peptide: "DSIP",
    category: "Sleep",
    title: "Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study",
    authors: "Bes F, et al.",
    year: "1992",
    journal: "Neuropsychobiology",
    pubmedId: "1299794",
    url: "https://pubmed.ncbi.nlm.nih.gov/1299794/",
    keyFindings: "DSIP showed slightly higher sleep efficiency and shorter sleep latency compared to placebo in chronic insomniacs, but the effects were weak and not considered of major therapeutic benefit.",
    evidenceLevel: "Randomized Controlled Trial",
    citations: 21,
    fdaStatus: "Investigational"
  },
  {
    id: "s44",
    peptide: "DSIP",
    category: "Sleep",
    title: "Delta-sleep-inducing peptide (DSIP): A review",
    authors: "Graf MV, Kastin AJ.",
    year: "1984",
    journal: "Neuroscience & Biobehavioral Reviews",
    pubmedId: "6145137",
    url: "https://www.sciencedirect.com/science/article/pii/0149763484900228",
    keyFindings: "This review summarizes the early research on DSIP, a nonapeptide that induces delta-sleep in various species. It also discusses DSIP's effects on brain activity, neurotransmitter levels, and hormonal regulation.",
    evidenceLevel: "Review",
    citations: 126,
    fdaStatus: "Research Only"
  },
  {
    id: "s45",
    peptide: "DSIP",
    category: "Sleep",
    title: "Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models",
    authors: "Liu X, et al.",
    year: "2024",
    journal: "Frontiers in Pharmacology",
    pubmedId: "39399436",
    url: "https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1439536/full",
    keyFindings: "A fusion peptide of DSIP and a cell-penetrating peptide (DSIP-CBBBP) showed sleep-promoting effects in a mouse model of insomnia. The study suggests this fusion peptide could be a potential therapy for sleep-related disorders.",
    evidenceLevel: "Preclinical",
    citations: 1,
    fdaStatus: "Research Only"
  },
  {
    id: "s46",
    peptide: "Epithalon",
    category: "Longevity",
    title: "Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells",
    authors: "Khavinson VK, Bondarev IE, Butyugov AA",
    year: "2003",
    journal: "Bull Exp Biol Med",
    pubmedId: "12937682",
    url: "https://pubmed.ncbi.nlm.nih.gov/12937682/",
    keyFindings: "The study found that Epithalon peptide induced telomerase activity and telomere elongation in human somatic cells, suggesting it could prolong the life of cells.",
    evidenceLevel: "In Vitro",
    citations: 5,
    fdaStatus: "Research Only"
  },
  {
    id: "s47",
    peptide: "Epithalon",
    category: "Longevity",
    title: "Antioxidant properties of geroprotective peptides of the pineal gland",
    authors: "Kozina LS, Arutjunyan AV, Khavinson VK",
    year: "2007",
    journal: "Arch Gerontol Geriatr",
    pubmedId: "17317455",
    url: "https://pubmed.ncbi.nlm.nih.gov/17317455/",
    keyFindings: "This study showed that Epithalamin and its active fragment, Epitalon, have antioxidant properties and enhance the antioxidant defense system in old rats.",
    evidenceLevel: "Preclinical",
    citations: 5,
    fdaStatus: "Research Only"
  },
  {
    id: "s48",
    peptide: "Epithalon",
    category: "Longevity",
    title: "Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice",
    authors: "Kossoy G, Anisimov VN, Ben-Hur H, Kossoy N, Zusman I",
    year: "2006",
    journal: "In Vivo",
    pubmedId: "16634527",
    url: "https://pubmed.ncbi.nlm.nih.gov/16634527/",
    keyFindings: "The study found that Epitalon decreased the number of tumor-bearing mice with malignant tumors and prevented the development of metastases in mice.",
    evidenceLevel: "Preclinical",
    citations: 3,
    fdaStatus: "Research Only"
  },
  {
    id: "s49",
    peptide: "Fisetin",
    category: "Longevity",
    title: "Fisetin is a senotherapeutic that extends health and lifespan",
    authors: "Yousefzadeh MJ, et al.",
    year: "2018",
    journal: "EBioMedicine",
    pubmedId: "30279143",
    url: "https://pubmed.ncbi.nlm.nih.gov/30279143/",
    keyFindings: "This preclinical study found that fisetin, a natural product, has senotherapeutic activity in mice and human tissues, reducing the burden of senescent cells and extending health and lifespan.",
    evidenceLevel: "Preclinical",
    citations: 1058,
    fdaStatus: "Supplement"
  },
  {
    id: "s50",
    peptide: "Fisetin",
    category: "Longevity",
    title: "Fisetin as a Senotherapeutic Agent: Biopharmaceutical Properties and Crosstalk between Cell Senescence and Neuroprotection",
    authors: "Tranquilli, E., et al.",
    year: "2022",
    journal: "Molecules",
    pubmedId: "35164003",
    url: "https://pubmed.ncbi.nlm.nih.gov/35164003/",
    keyFindings: "This review highlights fisetin's potential as a senotherapeutic agent, discussing its neuroprotective effects and its ability to extend lifespan by reducing peroxidation and enhancing antioxidant responses.",
    evidenceLevel: "Review",
    citations: 25,
    fdaStatus: "Supplement"
  },
  {
    id: "s51",
    peptide: "Fisetin",
    category: "Longevity",
    title: "Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence",
    authors: "Mahoney, S. A., et al.",
    year: "2023",
    journal: "Aging Cell",
    pubmedId: "38062873",
    url: "https://pubmed.ncbi.nlm.nih.gov/38062873/",
    keyFindings: "This preclinical study in old mice demonstrated that intermittent fisetin supplementation improves arterial function by reducing cellular senescence, oxidative stress, and inflammation.",
    evidenceLevel: "Preclinical",
    fdaStatus: "Supplement"
  },
  {
    id: "s52",
    peptide: "FOXO4-DRI",
    category: "Longevity",
    title: "FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice",
    authors: "Zhang C, et al.",
    year: "2020",
    journal: "Aging (Albany NY)",
    pubmedId: "31959736",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC7053614/",
    keyFindings: "FOXO4-DRI selectively induces apoptosis in senescent Leydig cells, which can improve the testicular microenvironment and alleviate age-related testosterone insufficiency in aged mice.",
    evidenceLevel: "Preclinical",
    citations: 104,
    fdaStatus: "Research Only"
  },
  {
    id: "s53",
    peptide: "FOXO4-DRI",
    category: "Longevity",
    title: "Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes",
    authors: "Huang Y, et al.",
    year: "2021",
    journal: "Front. Bioeng. Biotechnol.",
    pubmedId: "34046354",
    url: "https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2021.677576/full",
    keyFindings: "FOXO4-DRI can selectively remove senescent cells from in vitro expanded human chondrocytes, which could potentially improve the quality of cartilage regeneration.",
    evidenceLevel: "In Vitro",
    citations: 51,
    fdaStatus: "Research Only"
  },
  {
    id: "s54",
    peptide: "FOXO4-DRI",
    category: "Longevity",
    title: "FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells",
    authors: "Li Y, et al.",
    year: "2024",
    journal: "Experimental Gerontology",
    pubmedId: "38945440",
    url: "https://www.sciencedirect.com/science/article/pii/S0531556524001645",
    keyFindings: "In aged mice, FOXO4-DRI induced apoptosis in senescent Leydig cells, reduced the secretion of senescence-associated secretory phenotype, and improved spermatogenesis and sperm quality.",
    evidenceLevel: "Preclinical",
    citations: 9,
    fdaStatus: "Research Only"
  },
  {
    id: "s55",
    peptide: "Fragment 176-191",
    category: "Weight Management",
    title: "Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone",
    authors: "Ng FM, et al.",
    year: "2001",
    journal: "Horm Res",
    pubmedId: "11146367",
    url: "https://pubmed.ncbi.nlm.nih.gov/11146367/",
    keyFindings: "Daily oral administration of AOD9604 for 19 days significantly reduced body weight gain in obese rats and increased lipolytic activity in adipose tissues without adversely affecting insulin sensitivity. The study suggests AOD9604's potential as a safe oral therapy for obesity.",
    evidenceLevel: "Preclinical",
    citations: 50,
    fdaStatus: "Investigational"
  },
  {
    id: "s56",
    peptide: "Fragment 176-191",
    category: "Weight Management",
    title: "Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans",
    authors: "Stier H, et al.",
    year: "2013",
    journal: "J Endocrinol Metab",
    url: "https://www.jofem.org/index.php/jofem/article/view/157",
    keyFindings: "AOD9604 demonstrated a strong safety and tolerability profile in humans, comparable to a placebo. It did not cause adverse effects associated with hGH treatment, such as increased IGF-1 levels or insulin resistance.",
    evidenceLevel: "Clinical Trial",
    citations: 25,
    fdaStatus: "Investigational"
  },
  {
    id: "s57",
    peptide: "Fragment 176-191",
    category: "Weight Management",
    title: "The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and\u03b2 3 -AR Knock-Out Mice",
    authors: "Heffernan M, et al.",
    year: "2001",
    journal: "Endocrinology",
    url: "https://doi.org/10.1210/endo.142.12.8522",
    keyFindings: "Both hGH and AOD9604 can reduce body weight and body fat in obese mice after 14 days of treatment. This is correlated with an increase in the expression of \u03b23-AR RNA. The lipolytic actions of hGH and AOD9604 are not directly mediated through the \u03b23-AR, but both compounds increase \u03b23-AR expression, which may contribute to enhanced lipolytic sensitivity.",
    evidenceLevel: "Preclinical",
    citations: 30,
    fdaStatus: "Investigational"
  },
  {
    id: "s58",
    peptide: "GDF-11",
    category: "Regenerative",
    title: "Growth Differentiation Factor 11 Is a Circulating Factor that Reverses Age-Related Cardiac Hypertrophy",
    authors: "Loffredo FS, et al.",
    year: "2013",
    journal: "Cell",
    pubmedId: "23663781",
    url: "https://pubmed.ncbi.nlm.nih.gov/23663781/",
    keyFindings: "GDF11, a circulating factor in young mice that declines with age, can reverse age-related cardiac hypertrophy. Restoring GDF11 to youthful levels in old mice reversed age-related cardiac hypertrophy.",
    evidenceLevel: "Preclinical",
    citations: 1193,
    fdaStatus: "Research Only"
  },
  {
    id: "s59",
    peptide: "GDF-11",
    category: "Regenerative",
    title: "The role of GDF11 during inflammation \u2013 An overview",
    authors: "Machelak W, et al.",
    year: "2023",
    journal: "Life Sciences",
    pubmedId: "37011872",
    url: "https://pubmed.ncbi.nlm.nih.gov/37011872/",
    keyFindings: "This review describes the involvement of GDF11 in the regulation of acute and chronic inflammatory disorders. An anti-inflammatory effect of GDF11 was found in experimental colitis, psoriasis and arthritis, but it may act as a pro-inflammatory agent in liver fibrosis and renal injury.",
    evidenceLevel: "Review",
    citations: 23,
    fdaStatus: "Research Only"
  },
  {
    id: "s60",
    peptide: "GDF-11",
    category: "Regenerative",
    title: "GDF11 antagonizes TNF-\u03b1-induced inflammation and protects against the development of inflammatory arthritis in mice",
    authors: "Li W, et al.",
    year: "2019",
    journal: "FASEB J",
    pubmedId: "30407878",
    url: "https://pubmed.ncbi.nlm.nih.gov/30407878/",
    keyFindings: "GDF11 antagonizes TNF-\u03b1-induced inflammation in macrophages and protects against the development of inflammatory arthritis in mice. The study suggests that the NF-\u03baB pathway plays a critical role in the therapeutic effect of GDF11 in rheumatoid arthritis.",
    evidenceLevel: "Preclinical",
    citations: 51,
    fdaStatus: "Research Only"
  },
  {
    id: "s61",
    peptide: "GHK-Cu",
    category: "Skin/Cosmetic",
    title: "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data",
    authors: "Pickart L, Margolina A",
    year: "2018",
    journal: "International Journal of Molecular Sciences",
    pubmedId: "29986520",
    url: "https://pubmed.ncbi.nlm.nih.gov/29986520/",
    keyFindings: "The GHK-Cu peptide has multiple health-positive biological actions, including stimulating blood vessel and nerve outgrowth, increasing collagen and elastin synthesis, and supporting dermal fibroblasts. It also possesses anti-cancer, anti-inflammatory, and DNA repair properties.",
    evidenceLevel: "Review",
    fdaStatus: "Research Only"
  },
  {
    id: "s62",
    peptide: "GHK-Cu",
    category: "Skin/Cosmetic",
    title: "The potential of GHK as an anti-aging peptide",
    authors: "Dou Y, Lee A, Zhu L, Morton J, Ladiges W",
    year: "2020",
    journal: "Aging Pathobiology and Therapeutics",
    pubmedId: "35083444",
    url: "https://pubmed.ncbi.nlm.nih.gov/35083444/",
    keyFindings: "GHK-Cu promotes skin remodeling, wound healing, and regeneration, with significant antioxidant and anti-inflammatory effects. It may also reverse age-related cognitive decline by targeting inflammation and epigenetic pathways.",
    evidenceLevel: "Preclinical",
    fdaStatus: "Research Only"
  },
  {
    id: "s63",
    peptide: "GHK-Cu",
    category: "Skin/Cosmetic",
    title: "Intranasal GHK peptide enhances resilience to cognitive decline in aging mice",
    authors: "Tucker M, Keely A, Park JY, Rosenfeld M, Wezeman J, Mangalindan R, Ratner D, Ladiges W",
    year: "2023",
    journal: "bioRxiv",
    pubmedId: "38014118",
    url: "https://pubmed.ncbi.nlm.nih.gov/38014118/",
    keyFindings: "Intranasal administration of GHK-Cu in aging mice improved cognitive performance in spatial memory and learning tasks. It also reduced neuroinflammatory and axonal damage markers, suggesting it can enhance resilience to brain aging.",
    evidenceLevel: "Preclinical",
    fdaStatus: "Research Only"
  },
  {
    id: "s64",
    peptide: "GHK-Cu Serum",
    category: "Skin/Cosmetic",
    title: "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data",
    authors: "Pickart L, et al.",
    year: "2018",
    journal: "International Journal of Molecular Sciences",
    pubmedId: "29986520",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/",
    keyFindings: "GHK-Cu has multiple biological actions, including stimulating blood vessel and nerve outgrowth, increasing collagen, elastin, and glycosaminoglycan synthesis, as well as supporting the function of dermal fibroblasts. It also possesses powerful cell protective actions such as anti-cancer and anti-inflammatory actions, lung protection, and DNA repair.",
    evidenceLevel: "Review",
    citations: 198,
    fdaStatus: "Research Only"
  },
  {
    id: "s65",
    peptide: "GHK-Cu Serum",
    category: "Skin/Cosmetic",
    title: "The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging: Implications for Cognitive Health",
    authors: "Pickart L, et al.",
    year: "2012",
    journal: "Oxidative Medicine and Cellular Longevity",
    pubmedId: "22611434",
    url: "https://onlinelibrary.wiley.com/doi/abs/10.1155/2012/324832",
    keyFindings: "The human tripeptide GHK-Cu possesses antioxidant, anti-inflammatory, and regenerative properties. It can up- and downregulate a large number of human genes, suggesting its potential as a therapeutic agent against age-associated neurodegeneration and cognitive decline.",
    evidenceLevel: "Review",
    citations: 140,
    fdaStatus: "Research Only"
  },
  {
    id: "s66",
    peptide: "GHK-Cu Serum",
    category: "Skin/Cosmetic",
    title: "GHK-Cu may Prevent Oxidative Stress in Skin by Regulating Copper and Modifying Expression of Numerous Antioxidant Genes",
    authors: "Pickart L, et al.",
    year: "2015",
    journal: "Cosmetics",
    url: "https://www.mdpi.com/2079-9284/2/3/236",
    keyFindings: "GHK-Cu possesses antioxidant actions by blocking the formation of reactive oxygen and carbonyl species, detoxifying toxic products of lipid peroxidation, and protecting keratinocytes from UVB radiation. It also modulates the expression of numerous human genes, including many antioxidant-related genes.",
    evidenceLevel: "Review",
    citations: 57,
    fdaStatus: "Research Only"
  },
  {
    id: "s67",
    peptide: "GHRP-2",
    category: "Growth Hormone",
    title: "Growth Hormone Releasing Peptide-2 (GHRP-2), Like Ghrelin, Increases Food Intake in Healthy Men",
    authors: "Laferr\u00e8re B, et al.",
    year: "2005",
    journal: "The Journal of Clinical Endocrinology & Metabolism",
    pubmedId: "15699539",
    url: "https://pubmed.ncbi.nlm.nih.gov/15699539/",
    keyFindings: "GHRP-2, similar to ghrelin, was found to increase food intake in healthy men. This suggests that GHRP-2 could be a useful tool for studying the effects of ghrelin on eating behavior.",
    evidenceLevel: "Clinical Trial",
    citations: 85,
    fdaStatus: "Investigational"
  },
  {
    id: "s68",
    peptide: "GHRP-2",
    category: "Growth Hormone",
    title: "Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats",
    authors: "Granado M, et al.",
    year: "2005",
    journal: "American Journal of Physiology-Endocrinology and Metabolism",
    pubmedId: "15507538",
    url: "https://pubmed.ncbi.nlm.nih.gov/15507538/",
    keyFindings: "GHRP-2 administration showed an anti-inflammatory effect in arthritic rats, which appears to be mediated by ghrelin receptors on immune cells.",
    evidenceLevel: "Preclinical",
    citations: 251,
    fdaStatus: "Research Only"
  },
  {
    id: "s69",
    peptide: "GHRP-2",
    category: "Growth Hormone",
    title: "The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine",
    authors: "Phung LT, et al.",
    year: "2000",
    journal: "Domestic Animal Endocrinology",
    pubmedId: "10793268",
    url: "https://pubmed.ncbi.nlm.nih.gov/10793268/",
    keyFindings: "GHRP-2 stimulates the release of growth hormone and improves growth performance in swine.",
    evidenceLevel: "Preclinical",
    citations: 50,
    fdaStatus: "Research Only"
  },
  {
    id: "s70",
    peptide: "GHRP-6",
    category: "Growth Hormone",
    title: "The effects of GH-releasing peptide-6 (GHRP-6) and GHRP-2 on intracellular adenosine 3',5'-monophosphate (cAMP) levels and GH secretion in ovine and rat somatotrophs",
    authors: "D Wu et al.",
    year: "1996",
    journal: "J Endocrinol",
    pubmedId: "8699133",
    url: "https://pubmed.ncbi.nlm.nih.gov/8699133/",
    keyFindings: "GHRP-6 caused GH release without an increase in intracellular cAMP levels, and its effect was dependent on extracellular Ca2+ influx. This suggests that GHRP-6 acts on different receptors than GHRP-2 and GRF.",
    evidenceLevel: "Preclinical",
    citations: 5,
    fdaStatus: "Research Only"
  },
  {
    id: "s71",
    peptide: "GHRP-6",
    category: "Growth Hormone",
    title: "Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man",
    authors: "R M Frieboes et al.",
    year: "1995",
    journal: "Neuroendocrinology",
    pubmedId: "7617137",
    url: "https://pubmed.ncbi.nlm.nih.gov/7617137/",
    keyFindings: "GHRP-6 stimulates not only GH release but also hypothalamic-pituitary-adrenocortical hormone secretion, enhancing stage 2 sleep.",
    evidenceLevel: "Clinical Trial",
    citations: 5,
    fdaStatus: "Research Only"
  },
  {
    id: "s72",
    peptide: "GHRP-6",
    category: "Growth Hormone",
    title: "Epidermal growth factor and growth hormone-releasing peptide-6: combined therapeutic approach in experimental stroke",
    authors: "Diana Garc\u00eda Del Barco-Herrera et al.",
    year: "2013",
    journal: "Restor Neurol Neurosci",
    pubmedId: "23314006",
    url: "https://pubmed.ncbi.nlm.nih.gov/23314006/",
    keyFindings: "Co-treatment with EGF and GHRP-6 affects both the clinical and pathological outcomes in a global brain ischemia model, suggesting a suitable therapeutic approach for the acute management of stroke.",
    evidenceLevel: "Preclinical",
    citations: 3,
    fdaStatus: "Research Only"
  },
  {
    id: "s73",
    peptide: "GLP-1 Receptor Agonists",
    category: "Weight Management",
    title: "GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art",
    authors: "Nauck MA, et al.",
    year: "2021",
    journal: "Molecular Metabolism",
    pubmedId: "33068776",
    url: "https://www.sciencedirect.com/science/article/pii/S2212877820301769",
    keyFindings: "This review summarizes the current knowledge about GLP-1 receptor agonists. It highlights that they lower plasma glucose by affecting insulin and glucagon secretion and by slowing gastric emptying. They also lower body weight through central nervous system effects and reduce cardiovascular events.",
    evidenceLevel: "Review",
    citations: 1640,
    fdaStatus: "FDA Approved"
  },
  {
    id: "s74",
    peptide: "GLP-1 Receptor Agonists",
    category: "Weight Management",
    title: "A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond",
    authors: "Prasad-Reddy L, et al.",
    year: "2015",
    journal: "Drugs in Context",
    pubmedId: "26213556",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC4509428/",
    keyFindings: "This review discusses the efficacy and safety of GLP-1 receptor agonists, highlighting their benefits beyond glucose control, including positive effects on weight, blood pressure, and cholesterol. It also notes that once-weekly formulations may improve patient adherence.",
    evidenceLevel: "Review",
    citations: 472,
    fdaStatus: "FDA Approved"
  },
  {
    id: "s75",
    peptide: "GLP-1 Receptor Agonists",
    category: "Weight Management",
    title: "GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus",
    authors: "Meier JJ",
    year: "2012",
    journal: "Nature Reviews Endocrinology",
    pubmedId: "22945360",
    url: "https://pubmed.ncbi.nlm.nih.gov/22945360/",
    keyFindings: "This review discusses how the different pharmacokinetic and pharmacodynamic profiles of various GLP-1 receptor agonists might allow for individualized treatment of type 2 diabetes. Short-acting agonists primarily lower postprandial glucose, while long-acting ones have a stronger effect on fasting glucose.",
    evidenceLevel: "Review",
    citations: 1627,
    fdaStatus: "FDA Approved"
  },
  {
    id: "s76",
    peptide: "Glutathione",
    category: "Immune Support",
    title: "Randomized controlled trial of oral glutathione supplementation on body stores of glutathione",
    authors: "John P Richie Jr, et al.",
    year: "2015",
    journal: "Eur J Nutr",
    pubmedId: "24791752",
    url: "https://pubmed.ncbi.nlm.nih.gov/24791752/",
    keyFindings: "Daily consumption of GSH supplements was effective at increasing body compartment stores of GSH. GSH levels increased in a dose and time-dependent manner and returned to baseline after a washout period.",
    evidenceLevel: "Randomized Controlled Trial",
    citations: 219,
    fdaStatus: "Supplement"
  },
  {
    id: "s77",
    peptide: "Glutathione",
    category: "Immune Support",
    title: "Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function",
    authors: "Raghu Sinha, et al.",
    year: "2018",
    journal: "Eur J Clin Nutr",
    pubmedId: "28853742",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC6389332/",
    keyFindings: "Liposomal GSH administration elevated GSH stores and impacted immune function and levels of oxidative stress. NK cell cytotoxicity and lymphocyte proliferation were enhanced.",
    evidenceLevel: "Clinical Trial",
    citations: 175,
    fdaStatus: "Supplement"
  },
  {
    id: "s78",
    peptide: "Glutathione",
    category: "Immune Support",
    title: "A clinical trial of glutathione supplementation in autism spectrum disorders",
    authors: "JK Kern, et al.",
    year: "2011",
    journal: "Med Sci Monit",
    pubmedId: "22042115",
    url: "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3628138/",
    keyFindings: "This study found that both oral and transdermal glutathione supplementation improved some plasma glutathione metabolites and that transdermal glutathione also improved some of the ASD-related symptoms.",
    evidenceLevel: "Clinical Trial",
    citations: 109,
    fdaStatus: "Supplement"
  },
  {
    id: "s79",
    peptide: "Hexarelin",
    category: "Growth Hormone",
    title: "Growth hormone-releasing activity of hexarelin in humans. A dose-response study",
    authors: "B P Imbimbo et al.",
    year: "1994",
    journal: "Eur J Clin Pharmacol",
    pubmedId: "7957536",
    url: "https://pubmed.ncbi.nlm.nih.gov/7957536/",
    keyFindings: "Hexarelin stimulates the release of growth hormone in a dose-dependent manner in healthy human subjects. The effect is rapid, with a peak at about 30 minutes, and the half-life is about 55 minutes.",
    evidenceLevel: "Clinical Trial",
    citations: 92,
    fdaStatus: "Investigational"
  },
  {
    id: "s80",
    peptide: "Hexarelin",
    category: "Growth Hormone",
    title: "Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice",
    authors: "Rasha Mosa et al.",
    year: "2017",
    journal: "Endocrinology",
    pubmedId: "28977588",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC5659698/",
    keyFindings: "Hexarelin treatment significantly improved glucose and insulin intolerance and decreased plasma and liver triglycerides in mice. It also corrected abnormal body composition by decreasing fat mass and increasing lean mass.",
    evidenceLevel: "Preclinical",
    fdaStatus: "Research Only"
  },
  {
    id: "s81",
    peptide: "Hexarelin",
    category: "Growth Hormone",
    title: "The cardiovascular action of hexarelin",
    authors: "Yuanjie Mao et al.",
    year: "2014",
    journal: "J Geriatr Cardiol",
    pubmedId: "25278975",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC4178518/",
    keyFindings: "This review discusses the cardiovascular actions of hexarelin, noting its direct effects beyond growth hormone release, including positive inotropic and cardioprotective effects, mediated in part by the CD36 receptor.",
    evidenceLevel: "Review",
    citations: 40,
    fdaStatus: "Research Only"
  },
  {
    id: "s82",
    peptide: "Humanin",
    category: "Longevity",
    title: "The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan",
    authors: "Yen K, et al.",
    year: "2020",
    journal: "Aging (Albany NY)",
    pubmedId: "32575074",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC7343442/",
    keyFindings: "Humanin overexpression is sufficient to increase lifespan in C. elegans and improves metabolic healthspan parameters in mice. Humanin levels are also higher in the children of centenarians, suggesting a link to longevity.",
    evidenceLevel: "Preclinical",
    citations: 116,
    fdaStatus: "Research Only"
  },
  {
    id: "s83",
    peptide: "Humanin",
    category: "Longevity",
    title: "Humanin and Its Pathophysiological Roles in Aging: A Systematic Review",
    authors: "Coradduzza D, et al.",
    year: "2023",
    journal: "Biology (Basel)",
    pubmedId: "37106758",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC10135985/",
    keyFindings: "This systematic review summarizes the roles of humanin in aging and age-related diseases, highlighting its neuroprotective, anti-inflammatory, and anti-oxidative stress effects. It also discusses the potential of humanin as a therapeutic agent for these conditions.",
    evidenceLevel: "Review",
    citations: 45,
    fdaStatus: "Research Only"
  },
  {
    id: "s84",
    peptide: "Humanin",
    category: "Longevity",
    title: "The Molecular Structure and Role of Humanin in Neural and Skeletal Diseases, and in Tissue Regeneration",
    authors: "Zhu S, et al.",
    year: "2022",
    journal: "Frontiers in Cell and Developmental Biology",
    pubmedId: "35308573",
    url: "https://www.frontiersin.org/articles/10.3389/fcell.2022.823354/full",
    keyFindings: "This review discusses the molecular structure of humanin and its role in neural and skeletal diseases. It highlights the peptide's cytoprotective mechanisms and its potential for tissue regeneration.",
    evidenceLevel: "Review",
    citations: 34,
    fdaStatus: "Research Only"
  },
  {
    id: "s85",
    peptide: "Ibutamoren (MK-677)",
    category: "Growth Hormone",
    title: "Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized, Controlled Trial",
    authors: "Nass R, et al.",
    year: "2008",
    journal: "Annals of Internal Medicine",
    pubmedId: "18981485",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC2757071/",
    keyFindings: "Daily administration of MK-677 in healthy older adults significantly increased growth hormone and IGF-I levels to that of healthy young adults. This resulted in increased fat-free mass and a decrease in LDL (bad) cholesterol.",
    evidenceLevel: "Randomized, Controlled Trial",
    citations: 335,
    fdaStatus: "Investigational"
  },
  {
    id: "s86",
    peptide: "Ibutamoren (MK-677)",
    category: "Growth Hormone",
    title: "Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure",
    authors: "Svensson J, et al.",
    year: "1998",
    journal: "The Journal of Clinical Endocrinology & Metabolism",
    pubmedId: "9467555",
    url: "https://academic.oup.com/jcem/article-abstract/83/2/362/2865156",
    keyFindings: "Two-month treatment with MK-677 in healthy obese males caused a sustained increase in serum levels of GH, IGF-I, and IGF-binding protein-3. Changes in body composition and energy expenditure were of an anabolic nature, with a sustained increase in fat-free mass and a transient increase in basal metabolic rate.",
    evidenceLevel: "Randomized, double blind, parallel, and placebo controlled",
    citations: 229,
    fdaStatus: "Investigational"
  },
  {
    id: "s87",
    peptide: "Ibutamoren (MK-677)",
    category: "Growth Hormone",
    title: "Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects",
    authors: "Chapman IM, et al.",
    year: "1996",
    journal: "The Journal of Clinical Endocrinology & Metabolism",
    pubmedId: "8954023",
    url: "https://academic.oup.com/jcem/article-abstract/81/12/4249/2650464",
    keyFindings: "Daily oral administration of MK-677 to healthy older adults stimulated the GH-IGF-I axis and increased nitrogen retention, suggesting that it may be useful for treating age-related changes in body composition.",
    evidenceLevel: "Clinical Trial",
    citations: 337,
    fdaStatus: "Investigational"
  },
  {
    id: "s88",
    peptide: "IGF-1 LR3",
    category: "Growth Hormone",
    title: "Insulin-like growth factor-I (IGF-I) analogue, LR(3)IGF-I, ameliorates the loss of body weight but not of skeletal muscle during food restriction",
    authors: "F M Tomas et al.",
    year: "2001",
    journal: "Growth Horm IGF Res",
    pubmedId: "11472075",
    url: "https://pubmed.ncbi.nlm.nih.gov/11472075/",
    keyFindings: "In food-restricted rats, LR(3)IGF-I infusion helped maintain body weight and nitrogen retention but did not prevent muscle loss. It increased fat loss in young rats but exacerbated muscle protein breakdown in adult rats.",
    evidenceLevel: "Preclinical",
    fdaStatus: "Research Only"
  },
  {
    id: "s89",
    peptide: "IGF-1 LR3",
    category: "Growth Hormone",
    title: "IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep",
    authors: "Alicia White et al.",
    year: "2025",
    journal: "Am J Physiol Endocrinol Metab",
    pubmedId: "39679943",
    url: "https://pubmed.ncbi.nlm.nih.gov/39679943/",
    keyFindings: "A 1-week IGF-1 LR3 treatment in growth-restricted fetal sheep did not improve growth. While it didn't negatively impact insulin, it did decrease circulating amino acids, suggesting increased utilization.",
    evidenceLevel: "Preclinical",
    fdaStatus: "Research Only"
  },
  {
    id: "s90",
    peptide: "IGF-1 LR3",
    category: "Growth Hormone",
    title: "Optimizing IGF-I for skeletal muscle therapeutics",
    authors: "Anastassios Philippou et al.",
    year: "2014",
    journal: "Growth Horm IGF Res",
    pubmedId: "25002025",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC4665094/",
    keyFindings: "This review discusses the potential of IGF-I for muscle growth and repair. It covers strategies to optimize IGF-I therapies by focusing on bioavailability, potency, and tissue response.",
    evidenceLevel: "Review",
    fdaStatus: "Research Only"
  },
  {
    id: "s91",
    peptide: "Ipamorelin",
    category: "Growth Hormone",
    title: "Ipamorelin, the first selective growth hormone secretagogue",
    authors: "K Raun et al.",
    year: "1998",
    journal: "European Journal of Endocrinology",
    pubmedId: "9849822",
    url: "https://pubmed.ncbi.nlm.nih.gov/9849822/",
    keyFindings: "Ipamorelin is a potent and selective growth hormone secretagogue that stimulates GH release without significantly affecting other hormones like ACTH or cortisol. This makes it a promising candidate for clinical development.",
    evidenceLevel: "Preclinical",
    citations: 227,
    fdaStatus: "Investigational"
  },
  {
    id: "s92",
    peptide: "Ipamorelin",
    category: "Growth Hormone",
    title: "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients",
    authors: "David E Beck et al.",
    year: "2014",
    journal: "International Journal of Colorectal Disease",
    pubmedId: "25331030",
    url: "https://pubmed.ncbi.nlm.nih.gov/25331030/",
    keyFindings: "This phase 2 clinical trial found that Ipamorelin was well-tolerated but did not significantly reduce the time to first tolerated meal compared to placebo in patients recovering from bowel resection surgery.",
    evidenceLevel: "RCT",
    citations: 28,
    fdaStatus: "Investigational"
  },
  {
    id: "s93",
    peptide: "Ipamorelin",
    category: "Growth Hormone",
    title: "Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats",
    authors: "Peter B. Johansen et al.",
    year: "1999",
    journal: "Growth Hormone & IGF Research",
    pubmedId: "10442793",
    url: "https://www.sciencedirect.com/science/article/pii/S1096637499999987",
    keyFindings: "In this preclinical study, Ipamorelin was shown to dose-dependently increase longitudinal bone growth rate and body weight gain in rats, suggesting its potential for treating growth retardation.",
    evidenceLevel: "Preclinical",
    citations: 48,
    fdaStatus: "Investigational"
  },
  {
    id: "s94",
    peptide: "Kisspeptin-10",
    category: "Sexual Health",
    title: "Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men",
    authors: "George JT et al.",
    year: "2011",
    journal: "J Clin Endocrinol Metab",
    pubmedId: "21632807",
    url: "https://pubmed.ncbi.nlm.nih.gov/21632807/",
    keyFindings: "Kisspeptin-10 boluses potently evoke LH secretion in men, and continuous infusion increases testosterone, LH pulse frequency, and pulse size.",
    evidenceLevel: "Clinical Trial",
    citations: 225,
    fdaStatus: "Investigational"
  },
  {
    id: "s95",
    peptide: "Kisspeptin-10",
    category: "Sexual Health",
    title: "Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial",
    authors: "Mills EG et al.",
    year: "2023",
    journal: "JAMA Netw Open",
    pubmedId: "36735283",
    url: "https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2800937",
    keyFindings: "This randomized clinical trial investigates the physiological, behavioral, neural, and hormonal effects of kisspeptin administration in men with hypoactive sexual desire disorder.",
    evidenceLevel: "RCT",
    citations: 27,
    fdaStatus: "Investigational"
  },
  {
    id: "s96",
    peptide: "Kisspeptin-10",
    category: "Sexual Health",
    title: "Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men",
    authors: "Jayasena CN et al.",
    year: "2015",
    journal: "Hum Reprod",
    pubmedId: "26089302",
    url: "https://pubmed.ncbi.nlm.nih.gov/26089302/",
    keyFindings: "At the doses tested, intravenous administration of either of two major kisspeptin isoforms, kisspeptin-10 and -54, was associated with similar levels of gonadotrophin secretion in healthy men; however, GnRH was more potent when compared with either kisspeptin isoform.",
    evidenceLevel: "Clinical Trial",
    citations: 56,
    fdaStatus: "Investigational"
  },
  {
    id: "s97",
    peptide: "KPV Peptide",
    category: "Anti-Inflammatory",
    title: "PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation",
    authors: "Dalmasso G, et al.",
    year: "2007",
    journal: "Gastroenterology",
    pubmedId: "18061177",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC2431115/",
    keyFindings: "The study found that the tripeptide KPV can reduce intestinal inflammation by inhibiting key inflammatory pathways. This anti-inflammatory effect is mediated by the peptide transporter PepT1.",
    evidenceLevel: "Preclinical",
    citations: 132,
    fdaStatus: "Research Only"
  },
  {
    id: "s98",
    peptide: "KPV Peptide",
    category: "Anti-Inflammatory",
    title: "Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease",
    authors: "Kannengiesser K, et al.",
    year: "2008",
    journal: "Inflamm Bowel Dis",
    pubmedId: "18092346",
    url: "https://pubmed.ncbi.nlm.nih.gov/18092346/",
    keyFindings: "The study demonstrated that the tripeptide KPV has significant anti-inflammatory effects in mouse models of inflammatory bowel disease (IBD). These effects seem to be at least partially independent of MC1R signaling, suggesting KPV as a potential therapeutic option for IBD.",
    evidenceLevel: "Preclinical",
    citations: 69,
    fdaStatus: "Research Only"
  },
  {
    id: "s99",
    peptide: "KPV Peptide",
    category: "Anti-Inflammatory",
    title: "Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-\u03baB pathway",
    authors: "Sung J, et al.",
    year: "2025",
    journal: "Tissue and Cell",
    url: "https://www.sciencedirect.com/science/article/abs/pii/S004081662500117X",
    keyFindings: "This study shows that KPV protects skin cells from damage caused by fine dust by reducing oxidative stress and inflammation. It suggests that KPV could be a valuable ingredient in cosmetics and treatments for skin problems caused by pollution.",
    evidenceLevel: "In Vitro",
    citations: 1,
    fdaStatus: "Research Only"
  },
  {
    id: "s100",
    peptide: "LL-37",
    category: "Antimicrobial",
    title: "The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent",
    authors: "Ridyard KE, et al.",
    year: "2021",
    journal: "Antibiotics (Basel)",
    pubmedId: "34072318",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC8227053/",
    keyFindings: "The human antimicrobial peptide LL-37 has broad-spectrum antibacterial and anti-biofilm activities, as well as immunomodulatory functions, making it a promising candidate for novel antimicrobial therapies. However, limitations such as high cost, reduced activity in physiological environments, susceptibility to proteolytic degradation, and toxicity hinder regulatory approval.",
    evidenceLevel: "Review",
    citations: 270,
    fdaStatus: "Research Only"
  },
  {
    id: "s101",
    peptide: "LL-37",
    category: "Antimicrobial",
    title: "LL-37, the master antimicrobial peptide, its multifaceted role from combating infections to cancer immunity",
    authors: "Keshri AK, et al.",
    year: "2025",
    journal: "International Journal of Antimicrobial Agents",
    pubmedId: "39643165",
    url: "https://www.sciencedirect.com/science/article/abs/pii/S0924857924003145",
    keyFindings: "LL-37 effectively combats bacteria, fungi, and viruses, showing promise against antibiotic-resistant strains. Regulating inflammation and aiding in the defence against fungal infections, LL-37 influences immune responses. It disrupts biofilms, particularly in antibiotic-resistant bacteria, and displays both anti- and pro-cancerous effects, impacting immune responses and signalling pathways.",
    evidenceLevel: "Review",
    citations: 13,
    fdaStatus: "Research Only"
  },
  {
    id: "s102",
    peptide: "LL-37",
    category: "Antimicrobial",
    title: "Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity",
    authors: "Oren Z, et al.",
    year: "1999",
    journal: "Biochem J",
    pubmedId: "10417311",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC1220385/",
    keyFindings: "LL-37 is cytotoxic to both bacterial and normal eukaryotic cells. The study suggests a detergent-like effect via a 'carpet-like' mechanism on negatively charged membranes, and does not support the channel-forming hypothesis in zwitterionic membranes.",
    evidenceLevel: "In Vitro",
    fdaStatus: "Research Only"
  },
  {
    id: "s103",
    peptide: "Melanotan-1 (Afamelanotide)",
    category: "Skin/Cosmetic",
    title: "Afamelanotide for Erythropoietic Protoporphyria",
    authors: "Langendonk JG, et al.",
    year: "2015",
    journal: "N Engl J Med",
    pubmedId: "26132941",
    url: "https://pubmed.ncbi.nlm.nih.gov/26132941/",
    keyFindings: "Afamelanotide was associated with an increased duration of sun exposure without pain and improved quality of life in patients with erythropoietic protoporphyria.",
    evidenceLevel: "RCT",
    citations: 322,
    fdaStatus: "FDA Approved"
  },
  {
    id: "s104",
    peptide: "Melanotan-1 (Afamelanotide)",
    category: "Skin/Cosmetic",
    title: "Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders",
    authors: "Minder EI, et al.",
    year: "2017",
    journal: "Clin Pharmacokinet",
    pubmedId: "28063031",
    url: "https://pubmed.ncbi.nlm.nih.gov/28063031/",
    keyFindings: "This review summarizes the pharmacokinetics and pharmacodynamics of afamelanotide, its mechanism of action, and its clinical applications in various dermatologic disorders, highlighting its efficacy and safety profile.",
    evidenceLevel: "Review",
    citations: 80,
    fdaStatus: "FDA Approved"
  },
  {
    id: "s105",
    peptide: "Melanotan-1 (Afamelanotide)",
    category: "Skin/Cosmetic",
    title: "Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria",
    authors: "Wensink D, et al.",
    year: "2021",
    journal: "Expert Rev Clin Pharmacol",
    pubmedId: "33507118",
    url: "https://pubmed.ncbi.nlm.nih.gov/33507118/",
    keyFindings: "This review discusses the use of afamelanotide for preventing phototoxicity in patients with erythropoietic protoporphyria, concluding that it is an effective and well-tolerated treatment.",
    evidenceLevel: "Review",
    citations: 48,
    fdaStatus: "FDA Approved"
  },
  {
    id: "s106",
    peptide: "Melanotan-2",
    category: "Skin/Cosmetic",
    title: "Melanotan II: a possible cause of renal infarction: review of the literature and case report",
    authors: "Bj\u00f6rn Peters et al.",
    year: "2020",
    journal: "CEN Case Rep",
    pubmedId: "31953620",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC7148395/",
    keyFindings: "A case of renal infarction was most likely attributed to Melanotan II. The mechanism of renal injury with Melanotan II may involve thrombotic pharmacological influence and possible direct toxic effect on renal parenchyma.",
    evidenceLevel: "Case Report",
    citations: 13,
    fdaStatus: "Research Only"
  },
  {
    id: "s107",
    peptide: "Melanotan-2",
    category: "Skin/Cosmetic",
    title: "Poster presentationsPS09 User experiences of Melanotan II injection for tanning",
    authors: "Ning McKenzie et al.",
    year: "2024",
    journal: "British Journal of Dermatology",
    url: "https://academic.oup.com/bjd/article/191/Supplement_1/i179/7698506",
    keyFindings: "This qualitative study of 28 users found that all started MT2 for tanning, with some emphasizing burn prevention. Commonly reported side-effects include nausea, reversible darkening of moles, and an increase in libido or erections.",
    evidenceLevel: "Qualitative Study",
    fdaStatus: "Research Only"
  },
  {
    id: "s108",
    peptide: "Melanotan-2",
    category: "Skin/Cosmetic",
    title: "Evaluation of Melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study",
    authors: "Robert T. Dorr et al.",
    year: "1996",
    journal: "Life Sciences",
    pubmedId: "8614271",
    url: "https://www.sciencedirect.com/science/article/pii/0024320596001609",
    keyFindings: "MT-II has tanning activity in humans given only 5 low doses every other day by subcutaneous injection. Mild nausea was reported at most MT-II dose levels. A stretching and yawning complex appeared to correlate with the onset of spontaneous, penile erections.",
    evidenceLevel: "Clinical Trial",
    citations: 132,
    fdaStatus: "Investigational"
  },
  {
    id: "s109",
    peptide: "MGF (Mechano Growth Factor)",
    category: "Regenerative",
    title: "Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells",
    authors: "Fornaro M, et al.",
    year: "2014",
    journal: "Am J Physiol Endocrinol Metab",
    pubmedId: "24253050",
    url: "https://pubmed.ncbi.nlm.nih.gov/24253050/",
    keyFindings: "The study found that MGF peptides did not increase the proliferation of muscle cells (myoblasts) or inhibit their differentiation. These findings question the physiological role of MGF in muscle regeneration.",
    evidenceLevel: "In Vitro",
    citations: 53,
    fdaStatus: "Research Only"
  },
  {
    id: "s110",
    peptide: "MGF (Mechano Growth Factor)",
    category: "Regenerative",
    title: "Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages",
    authors: "Kandalla PK, et al.",
    year: "2011",
    journal: "Mech Ageing Dev",
    pubmedId: "21354439",
    url: "https://pubmed.ncbi.nlm.nih.gov/21354439/",
    keyFindings: "The MGF-E peptide significantly increased the proliferative life span and delayed senescence of satellite cells from neonatal and young adult muscle. This suggests that MGF could be a strategy to combat age-related sarcopenia.",
    evidenceLevel: "In Vitro",
    citations: 118,
    fdaStatus: "Research Only"
  },
  {
    id: "s111",
    peptide: "MGF (Mechano Growth Factor)",
    category: "Regenerative",
    title: "Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits",
    authors: "Deng M, et al.",
    year: "2011",
    journal: "Int Orthop",
    pubmedId: "21057789",
    url: "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3167400/",
    keyFindings: "MGF-Ct24E had the highest pro-proliferation activity on osteoblasts and promoted bone defect healing in rabbits. This suggests a new strategy for fracture healing.",
    evidenceLevel: "Preclinical",
    citations: 118,
    fdaStatus: "Research Only"
  },
  {
    id: "s112",
    peptide: "MOTS-c",
    category: "Metabolic",
    title: "MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation",
    authors: "Yuejun Zheng et al.",
    year: "2023",
    journal: "Front Endocrinol (Lausanne)",
    pubmedId: "36761202",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC9905433/",
    keyFindings: "MOTS-c is a mitochondrial-derived peptide that regulates gene expression and improves glucose metabolism, showing potential for treating diabetes, obesity, and aging-related diseases.",
    evidenceLevel: "Review",
    citations: 38,
    fdaStatus: "Research Only"
  },
  {
    id: "s113",
    peptide: "MOTS-c",
    category: "Metabolic",
    title: "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis",
    authors: "Joseph C Reynolds et al.",
    year: "2021",
    journal: "Nat Commun",
    pubmedId: "33473109",
    url: "https://pubmed.ncbi.nlm.nih.gov/33473109/",
    keyFindings: "MOTS-c enhances physical performance in mice and is induced by exercise in humans, regulating metabolism and promoting healthspan.",
    evidenceLevel: "Preclinical",
    citations: 203,
    fdaStatus: "Research Only"
  },
  {
    id: "s114",
    peptide: "MOTS-c",
    category: "Metabolic",
    title: "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance",
    authors: "Changhan Lee et al.",
    year: "2015",
    journal: "Cell Metab",
    pubmedId: "25738459",
    url: "https://pubmed.ncbi.nlm.nih.gov/25738459/",
    keyFindings: "MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity.",
    evidenceLevel: "Preclinical",
    citations: 803,
    fdaStatus: "Research Only"
  },
  {
    id: "s115",
    peptide: "NA-Semax",
    category: "Cognitive",
    title: "Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties",
    authors: "Magr\u00ec A, et al.",
    year: "2016",
    journal: "Journal of Inorganic Biochemistry",
    pubmedId: "27586814",
    url: "https://pubmed.ncbi.nlm.nih.gov/27586814/",
    keyFindings: "N-terminal acetylation of Semax alters its ability to bind with copper and zinc ions, which may affect its biological activity. The study suggests that the free amino terminus of Semax is crucial for its protective effects against copper-induced toxicity.",
    evidenceLevel: "Preclinical",
    citations: 10,
    fdaStatus: "Research Only"
  },
  {
    id: "s116",
    peptide: "NA-Semax",
    category: "Cognitive",
    title: "The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis",
    authors: "Medvedeva EV, et al.",
    year: "2014",
    journal: "BMC Genomics",
    pubmedId: "24661604",
    url: "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987924/",
    keyFindings: "Semax influences the expression of genes involved in the immune and vascular systems in a rat model of stroke. This suggests that the neuroprotective effects of Semax may be mediated by its immunomodulatory and vascular effects.",
    evidenceLevel: "Preclinical",
    citations: 20,
    fdaStatus: "Research Only"
  },
  {
    id: "s117",
    peptide: "NA-Semax",
    category: "Cognitive",
    title: "Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia\u2013Reperfusion in Rats",
    authors: "Filippenkov IB, et al.",
    year: "2020",
    journal: "Genes (Basel)",
    pubmedId: "32580520",
    url: "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350263/",
    keyFindings: "This study investigated the effect of Semax on gene expression in the rat brain after ischemia-reperfusion. It found that Semax administration led to significant changes in the expression of genes involved in various cellular processes, providing further insights into its neuroprotective mechanisms.",
    evidenceLevel: "Preclinical",
    citations: 15,
    fdaStatus: "Research Only"
  },
  {
    id: "s118",
    peptide: "NAC (N-Acetyl Cysteine)",
    category: "Immune Support",
    title: "N-Acetylcysteine (NAC): Impacts on Human Health",
    authors: "Micaely Cristina dos Santos Ten\u00f3rio et al.",
    year: "2021",
    journal: "Antioxidants (Basel)",
    pubmedId: "34208683",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC8234027/",
    keyFindings: "This review summarizes the various therapeutic uses of NAC, highlighting its role as an antioxidant and anti-inflammatory agent. It is effective in treating conditions related to oxidative stress, such as COPD and liver disease, by replenishing glutathione levels.",
    evidenceLevel: "Review",
    citations: 526,
    fdaStatus: "Supplement"
  },
  {
    id: "s119",
    peptide: "NAC (N-Acetyl Cysteine)",
    category: "Immune Support",
    title: "Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review",
    authors: "Slattery, J. et al.",
    year: "2015",
    journal: "Neuroscience and biobehavioral reviews",
    pubmedId: "25957927",
    url: "https://pubmed.ncbi.nlm.nih.gov/25957927/",
    keyFindings: "This systematic review provides evidence for the use of NAC in various psychiatric and neurological disorders, including autism, Alzheimer's disease, and addiction. It highlights NAC's role in addressing oxidative stress, neuroinflammation, and glutamate dysregulation in the brain.",
    evidenceLevel: "Systematic Review",
    citations: 509,
    fdaStatus: "Supplement"
  },
  {
    id: "s120",
    peptide: "NAC (N-Acetyl Cysteine)",
    category: "Immune Support",
    title: "A Review on Various Uses of N-Acetyl Cysteine",
    authors: "Mokhtari, V. et al.",
    year: "2017",
    journal: "Cell Journal",
    pubmedId: "28367412",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC5241507/",
    keyFindings: "This review discusses the diverse applications of NAC as a nutritional supplement and antioxidant. It highlights its use in treating various diseases due to its ability to scavenge free radicals and act as a precursor to glutathione.",
    evidenceLevel: "Review",
    citations: 16,
    fdaStatus: "Supplement"
  },
  {
    id: "s121",
    peptide: "NAD+",
    category: "Longevity",
    title: "Role of Nicotinamide Adenine Dinucleotide and Related Precursors as Therapeutic Targets for Age-Related Degenerative Diseases: Rationale, Biochemistry, Pharmacokinetics, and Outcomes",
    authors: "Braidy N, et al.",
    year: "2018",
    journal: "Antioxidants & Redox Signaling",
    pubmedId: "29634344",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC6277084/",
    keyFindings: "This review discusses the therapeutic potential of NAD+ and its precursors in age-related degenerative diseases. It highlights that boosting NAD+ levels can mitigate oxidative cell damage and may reverse aspects of aging.",
    evidenceLevel: "Review",
    citations: 304,
    fdaStatus: "Supplement"
  },
  {
    id: "s122",
    peptide: "NAD+",
    category: "Longevity",
    title: "Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions",
    authors: "Freeberg KA, et al.",
    year: "2023",
    journal: "The Journals of Gerontology: Series A",
    pubmedId: "37068054",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC10692436/",
    keyFindings: "This review summarizes the current knowledge on dietary supplementation with NAD+-boosting compounds in humans. It concludes that while supplementation is safe and increases NAD+ metabolites, more robust clinical trials are needed to determine the physiological benefits.",
    evidenceLevel: "Review",
    citations: 56,
    fdaStatus: "Supplement"
  },
  {
    id: "s123",
    peptide: "NAD+",
    category: "Longevity",
    title: "A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects",
    authors: "Dollerup OL, et al.",
    year: "2018",
    journal: "The American Journal of Clinical Nutrition",
    pubmedId: "29927732",
    url: "https://www.sciencedirect.com/science/article/pii/S0002916522029409",
    keyFindings: "This randomized, placebo-controlled clinical trial found that 12 weeks of nicotinamide riboside (NR) supplementation at 2000 mg/day was safe but did not improve insulin sensitivity or whole-body glucose metabolism in obese, insulin-resistant men.",
    evidenceLevel: "RCT",
    citations: 315,
    fdaStatus: "Supplement"
  },
  {
    id: "s124",
    peptide: "NAD+ Nasal Spray",
    category: "Neuroprotective",
    title: "Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia",
    authors: "Weihai Ying et al.",
    year: "2007",
    journal: "Frontiers in Bioscience",
    pubmedId: "17127275",
    url: "https://pubmed.ncbi.nlm.nih.gov/17127275/",
    keyFindings: "Intranasal NAD+ delivery significantly increased NAD+ content in the brain and profoundly decreased infarct formation and neurological deficits after ischemia in rats.",
    evidenceLevel: "Preclinical",
    citations: 199,
    fdaStatus: "Research Only"
  },
  {
    id: "s125",
    peptide: "NAD+ Nasal Spray",
    category: "Neuroprotective",
    title: "Prevention of Traumatic Brain Injury-Induced Neuron Death by Intranasal Delivery of Nicotinamide Adenine Dinucleotide",
    authors: "Seok Joon Won et al.",
    year: "2012",
    journal: "Journal of Neurotrauma",
    pubmedId: "22352983",
    url: "https://pubmed.ncbi.nlm.nih.gov/22352983/",
    keyFindings: "Intranasal administration of NAD+ immediately after TBI protected neurons in the hippocampus and reduced delayed microglial activation.",
    evidenceLevel: "Preclinical",
    citations: 130,
    fdaStatus: "Research Only"
  },
  {
    id: "s126",
    peptide: "NAD+ Nasal Spray",
    category: "Neuroprotective",
    title: "NAD+ metabolism and its roles in cellular processes during ageing",
    authors: "Anthony J Covarrubias et al.",
    year: "2021",
    journal: "Nature Reviews Molecular Cell Biology",
    pubmedId: "33353981",
    url: "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7963035/",
    keyFindings: "This review discusses how NAD+ levels decline with age, contributing to age-related diseases, and how restoring NAD+ levels may be a therapeutic strategy to ameliorate these conditions.",
    evidenceLevel: "Review",
    citations: 1540,
    fdaStatus: "Research Only"
  },
  {
    id: "s127",
    peptide: "NMN",
    category: "Longevity",
    title: "The efficacy and safety of \u03b2-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial",
    authors: "Lin Yi et al.",
    year: "2023",
    journal: "Geroscience",
    pubmedId: "36482258",
    url: "https://pubmed.ncbi.nlm.nih.gov/36482258/",
    keyFindings: "NMN supplementation increases blood NAD concentrations and is safe and well tolerated with oral dosing up to 900 mg NMN daily. Clinical efficacy expressed by blood NAD concentration and physical performance reaches highest at a dose of 600 mg daily oral intake.",
    evidenceLevel: "Randomized Controlled Trial",
    fdaStatus: "Investigational"
  },
  {
    id: "s128",
    peptide: "NMN",
    category: "Longevity",
    title: "Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials",
    authors: "Jiaqi Zhang et al.",
    year: "2024",
    journal: "Critical Reviews in Food Science and Nutrition",
    pubmedId: "2387324",
    url: "https://www.tandfonline.com/doi/full/10.1080/10408398.2024.2387324",
    keyFindings: "A surge of public interest in NMN supplementation has been observed in recent years. However, whether NMN supplements are effective in improving metabolic health remains unclear. The objective of the review was to assess the effects of NMN supplementation on fasting glucose, triglycerides, total cholesterol, LDL-C, and HDL-C in adults.",
    evidenceLevel: "Meta-Analysis",
    fdaStatus: "Supplement"
  },
  {
    id: "s129",
    peptide: "NMN",
    category: "Longevity",
    title: "The Science Behind NMN\u2013A Stable, Reliable NAD+Activator and Anti-Aging Molecule",
    authors: "Christopher Shade",
    year: "2020",
    journal: "Integrative Medicine: A Clinician's Journal",
    pubmedId: "32549859",
    url: "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238909/",
    keyFindings: "NMN supplementation has increased NAD+ biosynthesis, suppressed age-related adipose tissue inflammation, enhanced insulin secretion and insulin action, improved mitochondrial function, improved neuronal function in the brain, and more.",
    evidenceLevel: "Review",
    fdaStatus: "Supplement"
  },
  {
    id: "s130",
    peptide: "Noopept",
    category: "Cognitive",
    title: "Noopept; a nootropic dipeptide, modulates persistent inflammation by effecting spinal microglia dependent Brain Derived Neurotropic Factor (BDNF) and pro-BDNF expression throughout apoptotic process",
    authors: "Taghizadeh M, et al.",
    year: "2021",
    journal: "Heliyon",
    pubmedId: "33644478",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC7895721/",
    keyFindings: "Noopept can decrease spinal cell apoptosis and hyperalgesia during CFA-induced inflammation due to its direct effects on microglial activity and microglia dependent BDNF and pro-BDNF expressions. The anti-inflammatory and anti-hyperalgesic effects of Noopept may be mediated via inhibition of microglial activity and apoptosis.",
    evidenceLevel: "Preclinical",
    fdaStatus: "Research Only"
  },
  {
    id: "s131",
    peptide: "Noopept",
    category: "Cognitive",
    title: "Evaluation of Noopept Effect on the Neurotransmitter Amino Acids in the Hippocampus in Alcohol Drinking Rats Using in Vivo Microdialysis",
    authors: "Kudrin VS, et al.",
    year: "2024",
    journal: "Neurochemical Journal",
    pubmedId: "653901",
    url: "https://journals.eco-vector.com/1027-8133/article/view/653901",
    keyFindings: "In intact rats, Noopept increased the levels of both excitatory (ASP, GLU) and inhibitory (GLI) amino acids in the hippocampus. However, in rats chronically exposed to ethanol, the neurochemical mechanisms appeared insensitive to acute Noopept administration, suggesting that long-term alcohol exposure may alter the response to Noopept.",
    evidenceLevel: "Preclinical",
    fdaStatus: "Research Only"
  },
  {
    id: "s132",
    peptide: "Noopept",
    category: "Cognitive",
    title: "The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model",
    authors: "Ostrovskaya RU, et al.",
    year: "2007",
    journal: "Journal of Psychopharmacology",
    pubmedId: "17090676",
    url: "https://journals.sagepub.com/doi/abs/10.1177/0269881106071335",
    keyFindings: "Noopept restored spatial memory and increased serum antibody levels to oligomers of A\u03b2 (25\u201435) peptide in bulbectomized mice, an animal model of Alzheimer's disease. This suggests that Noopept may be useful for improving cognitive deficits in neurodegenerative diseases.",
    evidenceLevel: "Preclinical",
    fdaStatus: "Research Only"
  },
  {
    id: "s133",
    peptide: "Oxytocin",
    category: "Sexual Health",
    title: "A randomized, double-blind, placebo-controlled clinical trial of 8-week intranasal oxytocin administration in adults with obesity: Rationale, study design, and methods",
    authors: "Marie-Louis Wronski et al.",
    year: "2022",
    journal: "Contemp Clin Trials",
    pubmedId: "36087842",
    url: "https://pubmed.ncbi.nlm.nih.gov/36087842/",
    keyFindings: "This study investigates the efficacy, safety, and mechanisms of intranasal oxytocin for weight loss in adults with obesity. The results showed that the study sample is diverse with 38% identifying as non-White and 20% Hispanic.",
    evidenceLevel: "Clinical Trial",
    citations: 15,
    fdaStatus: "Investigational"
  },
  {
    id: "s134",
    peptide: "Oxytocin",
    category: "Sexual Health",
    title: "The orgasmic history of oxytocin: Love, lust, and labor",
    authors: "Navneet Magon et al.",
    year: "2011",
    journal: "Indian J Endocrinol Metab",
    pubmedId: "22029018",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC3183515/",
    keyFindings: "This review article discusses the various roles of oxytocin, from its traditional role in childbirth to its emerging role in social bonding, sexual behavior, and other physiological and pathological functions.",
    evidenceLevel: "Review",
    citations: 291,
    fdaStatus: "Research Only"
  },
  {
    id: "s135",
    peptide: "Oxytocin",
    category: "Sexual Health",
    title: "The role of oxytocin in psychiatric disorders: A review of biological and therapeutic research findings",
    authors: "David Cochran et al.",
    year: "2013",
    journal: "Harv Rev Psychiatry",
    pubmedId: "24651556",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC4120070/",
    keyFindings: "This review examines the literature on oxytocin dysfunction in psychiatric disorders like autism, schizophrenia, mood, and anxiety disorders, and discusses the potential for oxytocin-based therapies.",
    evidenceLevel: "Review",
    fdaStatus: "Research Only"
  },
  {
    id: "s136",
    peptide: "P21",
    category: "Cognitive",
    title: "Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice",
    authors: "Bin Li, et al.",
    year: "2010",
    journal: "FEBS Letters",
    pubmedId: "20600002",
    url: "https://pubmed.ncbi.nlm.nih.gov/20600002/",
    keyFindings: "P21, when administered peripherally, enhanced learning as well as both short-term and spatial reference memories of normal adult C57Bl6 mice. P21 induced enhancement of neurogenesis and maturation of newly born neurons in the granular cell layer and subgranular zone of the dentate gyrus.",
    evidenceLevel: "Preclinical",
    citations: 100,
    fdaStatus: "Research Only"
  },
  {
    id: "s137",
    peptide: "P21",
    category: "Cognitive",
    title: "Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder",
    authors: "Nicola Mottolese, et al.",
    year: "2024",
    journal: "Journal of Neurodevelopmental Disorders",
    pubmedId: "39592934",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC11590213/",
    keyFindings: "P021 treatment was effective in restoring neuronal proliferation, survival, and maturation deficits, as well as alterations in the GSK3\u03b2 signaling pathway, features that characterize a human neuronal model of CDKL5 deficiency. Unexpectedly, chronic in vivo P021 treatment failed to increase BDNF levels and did not improve neuroanatomical defects in _Cdkl_5 KO mice, resulting in limited behavioral benefit.",
    evidenceLevel: "Preclinical",
    fdaStatus: "Research Only"
  },
  {
    id: "s138",
    peptide: "P21",
    category: "Cognitive",
    title: "Enhancement of Neurogenesis and Memory by a Neurotrophic Peptide in Mild to Moderate Traumatic Brain Injury",
    authors: "Chohan MO, et al.",
    year: "2015",
    journal: "Neurosurgery",
    pubmedId: "25255260",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC4963295/",
    keyFindings: "Peptide 6 increased neurogenesis, reversed dendritic and synaptic density loss, and improved memory in TBI mice.",
    evidenceLevel: "Preclinical",
    citations: 50,
    fdaStatus: "Research Only"
  },
  {
    id: "s139",
    peptide: "Pinealon",
    category: "Cognitive",
    title: "[EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION]",
    authors: "V N Meshchaninov et al.",
    year: "2015",
    journal: "Adv Gerontol",
    pubmedId: "26390612",
    url: "https://pubmed.ncbi.nlm.nih.gov/26390612/",
    keyFindings: "The preparations of \"Pinealon\" and \"Vesugen\" have had the significant anabolic effect. They have improved the activity of the Central nervous system and other vital organs, which slows the rate of aging by biological age indicators.",
    evidenceLevel: "Clinical Trial",
    citations: 1,
    fdaStatus: "Research Only"
  },
  {
    id: "s140",
    peptide: "Pinealon",
    category: "Cognitive",
    title: "Pinealon Increases Cell Viability by Suppression of Free Radical Levels and Activating Proliferative Processes",
    authors: "V. Khavinson et al.",
    year: "2011",
    journal: "Rejuvenation Research",
    pubmedId: "21854157",
    url: "https://www.liebertpub.com/doi/10.1089/rej.2011.1172",
    keyFindings: "The synthetic tripeptide pinealon (Glu-Asp-Arg) demonstrates dose-dependent restriction of reactive oxygen species (ROS) accumulation in cerebellar granule cells, neutrophils, and pheochromocytoma (PC12) cells, induced by oxidative stress stimulated by receptor-dependent or -independent processes.",
    evidenceLevel: "In Vitro",
    citations: 42,
    fdaStatus: "Research Only"
  },
  {
    id: "s141",
    peptide: "Pinealon",
    category: "Cognitive",
    title: "Pinealon corrects hyperhomocysteinemia-induced disturbances of the diurnal dynamics of hypothalamic norepinephrine content in female rats",
    authors: "A. V. Korenevskii et al.",
    year: "2014",
    journal: "Neurochemical Journal",
    url: "https://link.springer.com/article/10.1134/S1819712414030088",
    keyFindings: "The data we obtained testify to the protective effect of pinealon and to its ability to diminish the unfavorable effect of hyperhomocysteinemia on the female rat reproductive function.",
    evidenceLevel: "Preclinical",
    citations: 5,
    fdaStatus: "Research Only"
  },
  {
    id: "s142",
    peptide: "PT-141 (Bremelanotide)",
    category: "Sexual Health",
    title: "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials",
    authors: "Sheryl A Kingsberg et al.",
    year: "2019",
    journal: "Obstet Gynecol",
    pubmedId: "31599840",
    url: "https://pubmed.ncbi.nlm.nih.gov/31599840/",
    keyFindings: "Bremelanotide significantly improved sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder. The safety profile was favorable.",
    evidenceLevel: "RCT",
    citations: 158,
    fdaStatus: "FDA Approved"
  },
  {
    id: "s143",
    peptide: "PT-141 (Bremelanotide)",
    category: "Sexual Health",
    title: "PT-141: a melanocortin agonist for the treatment of sexual dysfunction",
    authors: "P B Molinoff et al.",
    year: "2003",
    journal: "Ann N Y Acad Sci",
    pubmedId: "12851303",
    url: "https://pubmed.ncbi.nlm.nih.gov/12851303/",
    keyFindings: "Administration of PT-141 to normal men and to patients with erectile dysfunction resulted in a rapid dose-dependent increase in erectile activity.",
    evidenceLevel: "Clinical Trial",
    citations: 134,
    fdaStatus: "Investigational"
  },
  {
    id: "s144",
    peptide: "PT-141 (Bremelanotide)",
    category: "Sexual Health",
    title: "An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist",
    authors: "Lisa E. Diamond et al.",
    year: "2006",
    journal: "The Journal of Sexual Medicine",
    pubmedId: "16839319",
    url: "https://pubmed.ncbi.nlm.nih.gov/16839319/",
    keyFindings: "This preliminary evaluation suggests the potential for bremelanotide to positively affect desire and arousal in women with female sexual arousal disorder.",
    evidenceLevel: "Clinical Trial",
    citations: 147,
    fdaStatus: "Investigational"
  },
  {
    id: "s145",
    peptide: "Pterostilbene",
    category: "Longevity",
    title: "A Review of Pterostilbene Antioxidant Activity and Disease Modification",
    authors: "McCormack D, McFadden D",
    year: "2013",
    journal: "Oxidative Medicine and Cellular Longevity",
    pubmedId: "23691264",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC3649683/",
    keyFindings: "Pterostilbene, a natural compound in blueberries, has greater bioavailability than other stilbenes. Its antioxidant properties show potential in preventing and treating a wide range of diseases, including cancer, neurodegenerative disorders, cardiovascular disease, and diabetes.",
    evidenceLevel: "Review",
    citations: 409,
    fdaStatus: "Supplement"
  },
  {
    id: "s146",
    peptide: "Pterostilbene",
    category: "Longevity",
    title: "Effects of Pterostilbene on Cardiovascular Health and Disease",
    authors: "Tian R, Miao L, Cheang WS",
    year: "2024",
    journal: "Current Issues in Molecular Biology",
    pubmedId: "39329921",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC11430207/",
    keyFindings: "Pterostilbene has remarkable anti-inflammatory and antioxidant effects, with high bioavailability and low toxicity, showing potential therapeutic roles in treating cardiovascular diseases by targeting processes such as inflammation, oxidative stress, lipid metabolism, and cell proliferation.",
    evidenceLevel: "Review",
    citations: 50,
    fdaStatus: "Supplement"
  },
  {
    id: "s147",
    peptide: "Pterostilbene",
    category: "Longevity",
    title: "Analysis of Safety from a Human Clinical Trial with Pterostilbene",
    authors: "Riche DM, McEwen CL, Riche KD, et al.",
    year: "2013",
    journal: "Journal of Toxicology",
    pubmedId: "23431291",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC3575612/",
    keyFindings: "This clinical trial evaluated the safety of long-term pterostilbene administration in humans. The results showed that pterostilbene is generally safe for use in humans up to 250 mg/day, with no significant adverse effects on liver, kidney, or glucose markers.",
    evidenceLevel: "Clinical Trial",
    citations: 227,
    fdaStatus: "Supplement"
  },
  {
    id: "s148",
    peptide: "Quercetin",
    category: "Anti-Inflammatory",
    title: "Recent Advances in Potential Health Benefits of Quercetin",
    authors: "Fatemeh Aghababaei, Milad Hadidi",
    year: "2023",
    journal: "Pharmaceuticals (Basel)",
    pubmedId: "37513932",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC10384403/",
    keyFindings: "Quercetin has strong antioxidant properties that allow it to get rid of free radicals, lower oxidative stress, and protect cells from damage. Its anti-inflammatory properties, which include stopping the production of inflammatory cytokines and enzymes, make it a possible treatment for a number of inflammatory conditions.",
    evidenceLevel: "Review",
    citations: 605,
    fdaStatus: "Supplement"
  },
  {
    id: "s149",
    peptide: "Quercetin",
    category: "Anti-Inflammatory",
    title: "The effect of quercetin supplementation on the components of metabolic syndrome in adults: A systematic review and dose\u2013response meta-analysis of randomized controlled trials",
    authors: "Nooshin Noshadi et al.",
    year: "2024",
    journal: "Journal of Functional Foods",
    url: "https://www.sciencedirect.com/science/article/pii/S1756464624001774",
    keyFindings: "Quercetin supplementation significantly reduced fasting blood glucose and systolic blood pressure in adults. However, it did not have a significant effect on other components of metabolic syndrome such as triglycerides, HDL cholesterol, waist circumference, and diastolic blood pressure.",
    evidenceLevel: "Meta-Analysis",
    citations: 22,
    fdaStatus: "Supplement"
  },
  {
    id: "s150",
    peptide: "Quercetin",
    category: "Anti-Inflammatory",
    title: "Quercetin, Inflammation and Immunity",
    authors: "Yao Li et al.",
    year: "2016",
    journal: "Nutrients",
    pubmedId: "26999194",
    url: "https://www.mdpi.com/2072-6643/8/3/167",
    keyFindings: "Quercetin, a plant-derived polyphenol, demonstrates a wide array of biological activities, including anti-carcinogenic, anti-inflammatory, and antiviral effects. It also mitigates lipid peroxidation, platelet aggregation, and capillary permeability. This review focuses on the anti-inflammatory and immunomodulatory properties of quercetin, summarizing its effects on immune cells and inflammatory signaling pathways.",
    evidenceLevel: "Review",
    citations: 1674,
    fdaStatus: "Supplement"
  },
  {
    id: "s151",
    peptide: "Rapamycin (Sirolimus)",
    category: "Longevity",
    title: "Rapamycin for longevity: opinion article",
    authors: "Blagosklonny MV",
    year: "2019",
    journal: "Aging (Albany NY)",
    pubmedId: "31586989",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC6814615/",
    keyFindings: "The overwhelming evidence suggests that rapamycin is a universal anti-aging drug \u2013 that is, it extends lifespan in all tested models from yeast to mammals.",
    evidenceLevel: "Review",
    citations: 237,
    fdaStatus: "Investigational"
  },
  {
    id: "s152",
    peptide: "Rapamycin (Sirolimus)",
    category: "Longevity",
    title: "Rapamycin for longevity: the pros, the cons, and future perspectives",
    authors: "Roark KM, Iffland PH 2nd.",
    year: "2025",
    journal: "Frontiers in Aging",
    pubmedId: "1628187",
    url: "https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2025.1628187/full",
    keyFindings: "Rapamycin administration initiated in mid-life extends lifespan by 9%\u201314% in mice and is associated with delayed onset of age-related pathologies.",
    evidenceLevel: "Review",
    citations: 14,
    fdaStatus: "Investigational"
  },
  {
    id: "s153",
    peptide: "Rapamycin (Sirolimus)",
    category: "Longevity",
    title: "Targeting ageing with rapamycin and its derivatives in humans: a systematic review",
    authors: "Lozano-Torres D, et al.",
    year: "2024",
    journal: "The Lancet Healthy Longevity",
    pubmedId: "38272322",
    url: "https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(23)00258-1/fulltext",
    keyFindings: "Rapamycin and its derivatives improved physiological parameters associated with ageing in the immune, cardiovascular, and integumentary systems of healthy individuals or individuals with ageing-related diseases.",
    evidenceLevel: "Systematic Review",
    fdaStatus: "Investigational"
  },
  {
    id: "s154",
    peptide: "Resveratrol",
    category: "Longevity",
    title: "One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease",
    authors: "Tom\u00e9-Carneiro J, et al.",
    year: "2012",
    journal: "Am J Cardiol",
    pubmedId: "22520621",
    url: "https://pubmed.ncbi.nlm.nih.gov/22520621/",
    keyFindings: "A resveratrol-rich grape supplement taken for one year improved inflammatory and fibrinolytic markers in patients at high risk for cardiovascular disease. This suggests that resveratrol could be a useful supplement for the primary prevention of cardiovascular disease.",
    evidenceLevel: "Randomized Controlled Trial",
    citations: 342,
    fdaStatus: "Supplement"
  },
  {
    id: "s155",
    peptide: "Resveratrol",
    category: "Longevity",
    title: "Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women",
    authors: "Thaung Zaw JJ, et al.",
    year: "2020",
    journal: "Nutrients",
    pubmedId: "32244933",
    url: "https://www.mdpi.com/2072-6643/12/3/828",
    keyFindings: "Regular consumption of resveratrol for 12 months enhanced cognitive and cerebrovascular functions in postmenopausal women, suggesting it may help slow cognitive decline associated with aging and menopause.",
    evidenceLevel: "Randomized Controlled Trial",
    citations: 69,
    fdaStatus: "Supplement"
  },
  {
    id: "s156",
    peptide: "Resveratrol",
    category: "Longevity",
    title: "Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo-Controlled Trial",
    authors: "Wong RHX, et al.",
    year: "2020",
    journal: "J Bone Miner Res",
    pubmedId: "32564438",
    url: "https://pubmed.ncbi.nlm.nih.gov/32564438/",
    keyFindings: "Twice-daily supplementation with 75mg of resveratrol has the potential to slow bone loss in the lumbar spine and femoral neck in postmenopausal women, which are common sites for fractures.",
    evidenceLevel: "Randomized, Placebo-Controlled Trial",
    citations: 170,
    fdaStatus: "Supplement"
  },
  {
    id: "s157",
    peptide: "Retatrutide",
    category: "Weight Management",
    title: "Triple\u2013Hormone-Receptor Agonist Retatrutide for Obesity \u2014 A Phase 2 Trial",
    authors: "Ania M. Jastreboff, et al.",
    year: "2023",
    journal: "New England Journal of Medicine",
    pubmedId: "37366315",
    url: "https://www.nejm.org/doi/full/10.1056/NEJMoa2301972",
    keyFindings: "In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight.",
    evidenceLevel: "Clinical Trial",
    citations: 1001,
    fdaStatus: "Investigational"
  },
  {
    id: "s158",
    peptide: "Retatrutide",
    category: "Weight Management",
    title: "Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial",
    authors: "Tamer Coskun, et al.",
    year: "2025",
    journal: "The Lancet Diabetes & Endocrinology",
    pubmedId: "40609566",
    url: "https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00092-0/abstract",
    keyFindings: "Retatrutide demonstrated robust glucose and bodyweight reductions in participants with type 2 diabetes. This substudy assessed the change in total body fat mass.",
    evidenceLevel: "RCT",
    citations: 11,
    fdaStatus: "Investigational"
  },
  {
    id: "s159",
    peptide: "Retatrutide",
    category: "Weight Management",
    title: "Retatrutide showing promise in obesity (and type 2 diabetes)",
    authors: "Sheila A Doggrell",
    year: "2023",
    journal: "Expert Opinion on Investigational Drugs",
    pubmedId: "37947489",
    url: "https://www.tandfonline.com/doi/abs/10.1080/13543784.2023.2283020",
    keyFindings: "This review summarizes the phase 2 clinical trial of retatrutide in obesity, where weight loss ranged from -7.2% to -18% with increasing doses.",
    evidenceLevel: "Review",
    citations: 18,
    fdaStatus: "Investigational"
  },
  {
    id: "s160",
    peptide: "Selank",
    category: "Cognitive",
    title: "[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]",
    authors: "Zozulia AA, et al.",
    year: "2008",
    journal: "Zh Nevrol Psikhiatr Im S S Korsakova",
    pubmedId: "18454096",
    url: "https://pubmed.ncbi.nlm.nih.gov/18454096/",
    keyFindings: "The anxiolytic effects of Selank were found to be comparable to those of medazepam, a benzodiazepine drug. However, Selank also demonstrated additional anti-asthenic and psychostimulant properties.",
    evidenceLevel: "Randomized Controlled Trial",
    citations: 118,
    fdaStatus: "Investigational"
  },
  {
    id: "s161",
    peptide: "Selank",
    category: "Cognitive",
    title: "Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats",
    authors: "Kasian A, et al.",
    year: "2017",
    journal: "Behav Neurol",
    pubmedId: "28280289",
    url: "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322660/",
    keyFindings: "In rats under chronic stress, the combination of Selank and diazepam was most effective at reducing anxiety. On its own, Selank was also effective at reducing anxiety caused by the test substances themselves.",
    evidenceLevel: "Preclinical",
    citations: 23,
    fdaStatus: "Investigational"
  },
  {
    id: "s162",
    peptide: "Selank",
    category: "Cognitive",
    title: "Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission",
    authors: "Volkova A, et al.",
    year: "2016",
    journal: "Front Pharmacol",
    pubmedId: "26924983",
    url: "https://www.frontiersin.org/articles/10.3389/fphar.2016.00031/full",
    keyFindings: "Selank was found to alter the expression of numerous genes involved in neurotransmission, particularly within the GABAergic system. This suggests a complex, multi-faceted mechanism of action on nerve cells.",
    evidenceLevel: "Preclinical",
    citations: 27,
    fdaStatus: "Investigational"
  },
  {
    id: "s163",
    peptide: "Semax",
    category: "Cognitive",
    title: "Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome",
    authors: "Tsai SJ.",
    year: "2007",
    journal: "Med Hypotheses",
    pubmedId: "16996699",
    url: "https://pubmed.ncbi.nlm.nih.gov/16996699/",
    keyFindings: "This paper proposes that Semax may have good therapeutic potential in ADHD and Rett syndrome due to its ability to stimulate central brain-derived neurotrophic factor (BDNF) synthesis and augment the effects of psychostimulants on dopamine release.",
    evidenceLevel: "Review",
    citations: 20,
    fdaStatus: "Investigational"
  },
  {
    id: "s164",
    peptide: "Semax",
    category: "Cognitive",
    title: "The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis",
    authors: "Medvedeva EV, et al.",
    year: "2014",
    journal: "BMC Genomics",
    pubmedId: "24661604",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC3987924/",
    keyFindings: "In a rat model of stroke, Semax was found to modulate the expression of genes related to the immune and vascular systems, suggesting its neuroprotective effects may be mediated through these pathways.",
    evidenceLevel: "Preclinical",
    citations: 58,
    fdaStatus: "Research Only"
  },
  {
    id: "s165",
    peptide: "Semax",
    category: "Cognitive",
    title: "Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex",
    authors: "Romanova GA, et al.",
    year: "2006",
    journal: "Bull Exp Biol Med",
    pubmedId: "17603664",
    url: "https://pubmed.ncbi.nlm.nih.gov/17603664/",
    keyFindings: "Intranasal administration of Semax in rats with induced cerebral infarction decreased the size of the infarction and improved memory, demonstrating a neuroprotective and antiamnesic effect.",
    evidenceLevel: "Preclinical",
    citations: 27,
    fdaStatus: "Research Only"
  },
  {
    id: "s166",
    peptide: "Sermorelin",
    category: "Growth Hormone",
    title: "Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males",
    authors: "Sinha DK, et al.",
    year: "2020",
    journal: "Translational Andrology and Urology",
    pubmedId: "32257855",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC7108996/",
    keyFindings: "This review discusses the potential of growth hormone secretagogues (GHS) like sermorelin as an adjunctive therapy for hypogonadism. It highlights that GHS can improve body composition by increasing lean mass and reducing fat, but more research is needed to confirm their clinical efficacy.",
    evidenceLevel: "Review",
    citations: 65,
    fdaStatus: "Investigational"
  },
  {
    id: "s167",
    peptide: "Sermorelin",
    category: "Growth Hormone",
    title: "Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?",
    authors: "Walker RF",
    year: "2006",
    journal: "Clinical Interventions in Aging",
    pubmedId: "18046908",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC2699646/",
    keyFindings: "This article proposes sermorelin as a better alternative to recombinant human growth hormone (rhGH) for managing adult-onset growth hormone insufficiency. It suggests that sermorelin stimulates the body's own production of growth hormone, offering a more physiological and safer approach.",
    evidenceLevel: "Editorial",
    citations: 36,
    fdaStatus: "Investigational"
  },
  {
    id: "s168",
    peptide: "SLU-PP-332",
    category: "Metabolic",
    title: "A Synthetic ERR Agonist Alleviates Metabolic Syndrome",
    authors: "Billon C, et al.",
    year: "2024",
    journal: "The Journal of Pharmacology and Experimental Therapeutics",
    pubmedId: "37739806",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC10801787/",
    keyFindings: "SLU-PP-332 administration mimics exercise-induced benefits on whole-body metabolism in mice including increased energy expenditure and fatty acid oxidation. These effects were accompanied by decreased fat mass accumulation. Additionally, the ERR agonist effectively reduced obesity and improved insulin sensitivity in models of metabolic syndrome.",
    evidenceLevel: "Preclinical",
    fdaStatus: "Research Only"
  },
  {
    id: "s169",
    peptide: "SLU-PP-332",
    category: "Metabolic",
    title: "Synthetic ERR\u03b1/\u03b2/\u03b3 Agonist Induces an ERR\u03b1-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity",
    authors: "Billon C, et al.",
    year: "2023",
    journal: "ACS Chemical Biology",
    pubmedId: "36988910",
    url: "https://pubs.acs.org/doi/10.1021/acschembio.2c00720",
    keyFindings: "SLU-PP-332, a synthetic ERR pan agonist, increases mitochondrial function and cellular respiration in skeletal muscle cells. In mice, it increases type IIa oxidative skeletal muscle fibers and enhances exercise endurance.",
    evidenceLevel: "Preclinical",
    citations: 43,
    fdaStatus: "Research Only"
  },
  {
    id: "s170",
    peptide: "SLU-PP-332",
    category: "Metabolic",
    title: "Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function",
    authors: "Xu W, et al.",
    year: "2024",
    journal: "Circulation",
    pubmedId: "37961903",
    url: "https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.066542",
    keyFindings: "Both SLU-PP-332 and SLU-PP-915 significantly improved ejection fraction, ameliorated fibrosis, and increased survival associated with pressure overload\u2013induced HF without affecting cardiac hypertrophy. ERR agonists increase mitochondria oxidative capacity and fatty acid use in vitro and in vivo.",
    evidenceLevel: "Preclinical",
    citations: 55,
    fdaStatus: "Research Only"
  },
  {
    id: "s171",
    peptide: "Spermidine",
    category: "Longevity",
    title: "Spermidine delays aging in humans",
    authors: "Madeo F, et al.",
    year: "2018",
    journal: "Aging (Albany NY)",
    pubmedId: "30082504",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC6128428/",
    keyFindings: "External supply of the natural polyamine spermidine can extend life span in model organisms including yeast, nematodes, flies and mice. Recent epidemiological evidence suggests that increased uptake of spermidine with food also reduces overall, cardiovascular and cancer-related mortality in humans.",
    evidenceLevel: "Review",
    fdaStatus: "Supplement"
  },
  {
    id: "s172",
    peptide: "Spermidine",
    category: "Longevity",
    title: "Spermidine in health and disease",
    authors: "Madeo F, et al.",
    year: "2018",
    journal: "Science",
    pubmedId: "29371428",
    url: "https://www.science.org/doi/10.1126/science.aan2788",
    keyFindings: "Increased uptake of spermidine has protective effects against cancer, metabolic disease, heart disease, and neurodegeneration.",
    evidenceLevel: "Review",
    citations: 500,
    fdaStatus: "Supplement"
  },
  {
    id: "s173",
    peptide: "Spermidine",
    category: "Longevity",
    title: "Effects of Spermidine Supplementation on Cognition and Biomarkers in Older Adults With Subjective Cognitive Decline: A Randomized Clinical Trial",
    authors: "Schwarz C, et al.",
    year: "2022",
    journal: "JAMA Netw Open",
    pubmedId: "35616942",
    url: "https://pubmed.ncbi.nlm.nih.gov/35616942/",
    keyFindings: "In this randomized clinical trial, longer-term spermidine supplementation in participants with subjective cognitive decline did not modify memory and biomarkers compared with placebo. Exploratory analyses indicated possible beneficial effects on verbal memory and inflammation that need to be validated in future studies at higher dosage.",
    evidenceLevel: "RCT",
    citations: 10,
    fdaStatus: "Supplement"
  },
  {
    id: "s174",
    peptide: "SS-31 (Elamipretide)",
    category: "Regenerative",
    title: "Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial",
    authors: "Karaa A, et al.",
    year: "2023",
    journal: "Neurology",
    pubmedId: "37268435",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC10382259/",
    keyFindings: "Subcutaneous elamipretide treatment did not improve outcomes in the 6-minute walk test and fatigue scores in patients with primary mitochondrial myopathy. However, the treatment was well-tolerated.",
    evidenceLevel: "RCT",
    citations: 64,
    fdaStatus: "Investigational"
  },
  {
    id: "s175",
    peptide: "SS-31 (Elamipretide)",
    category: "Regenerative",
    title: "Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER",
    authors: "Thompson WR, et al.",
    year: "2024",
    journal: "Genetics in Medicine",
    url: "https://www.sciencedirect.com/science/article/pii/S1098360024000716",
    keyFindings: "Elamipretide was associated with sustained long-term tolerability and efficacy, with improvements in functional assessments and cardiac function in Barth syndrome.",
    evidenceLevel: "Clinical Trial",
    citations: 32,
    fdaStatus: "Investigational"
  },
  {
    id: "s176",
    peptide: "SS-31 (Elamipretide)",
    category: "Regenerative",
    title: "Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice",
    authors: "Zhao W, et al.",
    year: "2019",
    journal: "Journal of Neuroinflammation",
    pubmedId: "31747905",
    url: "https://pubmed.ncbi.nlm.nih.gov/31747905/",
    keyFindings: "Elamipretide may have a therapeutic potential in preventing damage from the oxidative stress and neuroinflammation that contribute to perioperative neurocognitive disorders (PND).",
    evidenceLevel: "Preclinical",
    citations: 186,
    fdaStatus: "Research Only"
  },
  {
    id: "s177",
    peptide: "TB-500 (Thymosin Beta-4)",
    category: "Regenerative",
    title: "Progress on the Function and Application of Thymosin \u03b24",
    authors: "Yuan Xing, et al.",
    year: "2021",
    journal: "Frontiers in Endocrinology",
    pubmedId: "34992578",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC8724243/",
    keyFindings: "This review summarizes the functions and applications of Thymosin \u03b24 (T\u03b24), a multifunctional peptide that plays a key role in angiogenesis, cell proliferation, apoptosis, and inflammation. T\u03b24 has shown potential in animal and clinical studies for treating various conditions, including myocardial infarction, xerophthalmia, and skin trauma.",
    evidenceLevel: "Review",
    citations: 62,
    fdaStatus: "Investigational"
  },
  {
    id: "s178",
    peptide: "TB-500 (Thymosin Beta-4)",
    category: "Regenerative",
    title: "Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies",
    authors: "Ildiko Bock-Marquette, et al.",
    year: "2023",
    journal: "International Immunopharmacology",
    pubmedId: "36709593",
    url: "https://pubmed.ncbi.nlm.nih.gov/36709593/",
    keyFindings: "This review proposes that Thymosin beta-4 (TB4) can be used to reverse cellular damage and promote organ regeneration. The authors found that TB4 is expressed in the developing heart and can improve cardiac function after a heart attack. They suggest that TB4 may be able to reactivate embryonic programs to accelerate organ regeneration.",
    evidenceLevel: "Review",
    citations: 18,
    fdaStatus: "Investigational"
  },
  {
    id: "s179",
    peptide: "TB-500 (Thymosin Beta-4)",
    category: "Regenerative",
    title: "Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing",
    authors: "Giorgio Guarnera, et al.",
    year: "2007",
    journal: "Annals of the New York Academy of Sciences",
    pubmedId: "17495250",
    url: "https://pubmed.ncbi.nlm.nih.gov/17495250/",
    keyFindings: "This was a double-blind, placebo-controlled, dose-escalation study to evaluate the safety and efficacy of topical Thymosin beta-4 (Tbeta-4) for the treatment of venous ulcers. The study found that Tbeta-4 was well-tolerated and showed a trend towards improved healing, although the study was not powered to show statistical significance.",
    evidenceLevel: "Randomized Controlled Trial",
    fdaStatus: "Investigational"
  },
  {
    id: "s180",
    peptide: "Tesamorelin",
    category: "Growth Hormone",
    title: "Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial",
    authors: "Stanley TL, Feldpausch MN, Oh J, et al.",
    year: "2014",
    journal: "JAMA",
    pubmedId: "25038357",
    url: "https://pubmed.ncbi.nlm.nih.gov/25038357/",
    keyFindings: "Tesamorelin significantly reduced visceral adipose tissue and liver fat in HIV-infected patients with abdominal fat accumulation.",
    evidenceLevel: "RCT",
    citations: 97,
    fdaStatus: "FDA Approved"
  },
  {
    id: "s181",
    peptide: "Tesamorelin",
    category: "Growth Hormone",
    title: "Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial",
    authors: "Stanley TL, Fourman LT, Feldpausch MN, et al.",
    year: "2019",
    journal: "The Lancet HIV",
    pubmedId: "31611038",
    url: "https://pubmed.ncbi.nlm.nih.gov/31611038/",
    keyFindings: "Tesamorelin reduces liver fat content and may be beneficial for patients with HIV and non-alcoholic fatty liver disease (NAFLD).",
    evidenceLevel: "RCT",
    citations: 92,
    fdaStatus: "Investigational"
  },
  {
    id: "s182",
    peptide: "Tesamorelin",
    category: "Growth Hormone",
    title: "Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial",
    authors: "Clemmons DR, Miller S, Mamputu JC.",
    year: "2017",
    journal: "PLoS One",
    pubmedId: "28617838",
    url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0179538",
    keyFindings: "Treatment of type 2 diabetic patients with tesamorelin for 12 weeks did not alter insulin response or glycemic control.",
    evidenceLevel: "RCT",
    citations: 27,
    fdaStatus: "Investigational"
  },
  {
    id: "s183",
    peptide: "Tesofensine",
    category: "Weight Management",
    title: "Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial",
    authors: "Astrup A, et al.",
    year: "2008",
    journal: "The Lancet",
    pubmedId: "18950853",
    url: "https://pubmed.ncbi.nlm.nih.gov/18950853/",
    keyFindings: "Tesofensine at 0.5mg produced a weight loss of 9.2%, significantly greater than placebo. It has the potential to produce a weight loss twice that of currently approved drugs.",
    evidenceLevel: "Randomized Controlled Trial",
    citations: 266,
    fdaStatus: "Investigational"
  },
  {
    id: "s184",
    peptide: "Tesofensine",
    category: "Weight Management",
    title: "Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity",
    authors: "Huynh K, et al.",
    year: "2022",
    journal: "European Journal of Endocrinology",
    pubmedId: "35294397",
    url: "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175551/",
    keyFindings: "Tesomet (tesofensine/metoprolol) was well-tolerated and resulted in significant weight loss in adults with hypothalamic obesity compared to placebo.",
    evidenceLevel: "Randomized Controlled Trial",
    citations: 42,
    fdaStatus: "Investigational"
  },
  {
    id: "s185",
    peptide: "Tesofensine",
    category: "Weight Management",
    title: "The effect of tesofensine on appetite sensations",
    authors: "Gilbert JA, et al.",
    year: "2012",
    journal: "Obesity (Silver Spring)",
    pubmedId: "21720440",
    url: "https://pubmed.ncbi.nlm.nih.gov/21720440/",
    keyFindings: "Tesofensine induced a dose-dependent increase in satiety that correlated with weight loss. Enhanced satiety is likely involved in the early weight loss effects of the drug.",
    evidenceLevel: "Randomized Controlled Trial",
    citations: 47,
    fdaStatus: "Investigational"
  },
  {
    id: "s186",
    peptide: "Vasoactive Intestinal Peptide",
    category: "Immune Support",
    title: "Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system",
    authors: "Iwasaki M, Akiba Y, Kaunitz JD",
    year: "2019",
    journal: "F1000Res",
    pubmedId: "31559013",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC6743256/",
    keyFindings: "VIP has multiple physiological and pathological effects on development, growth, and the control of neuronal, epithelial, and endocrine cell functions that in turn regulate ion secretion, nutrient absorption, gut motility, glycemic control, carcinogenesis, immune responses, and circadian rhythms.",
    evidenceLevel: "Review",
    fdaStatus: "Investigational"
  },
  {
    id: "s187",
    peptide: "Vasoactive Intestinal Peptide",
    category: "Immune Support",
    title: "The role of vasoactive intestinal peptide in pulmonary diseases",
    authors: "Zhong HL, Li PZ, Li D, Guan CX, Zhou Y",
    year: "2023",
    journal: "Life Sci",
    pubmedId: "37742737",
    url: "https://pubmed.ncbi.nlm.nih.gov/37742737/",
    keyFindings: "This review centers on the function of VIP in various lung diseases, such as pulmonary arterial hypertension, chronic obstructive pulmonary disease, asthma, cystic fibrosis, acute lung injury/acute respiratory distress syndrome, pulmonary fibrosis, and lung tumors.",
    evidenceLevel: "Review",
    fdaStatus: "Investigational"
  },
  {
    id: "s188",
    peptide: "Vasoactive Intestinal Peptide",
    category: "Immune Support",
    title: "Vasoactive intestinal peptide (VIP) prevents experimental arthritis",
    authors: "Delgado M, et al.",
    year: "2001",
    journal: "Nat Med",
    pubmedId: "11329061",
    url: "https://www.nature.com/articles/nm0501-563",
    keyFindings: "VIP has a therapeutic effect on an animal model of rheumatoid arthritis. This therapeutic effect is associated with downregulation of both inflammatory and autoimmune components of the disease.",
    evidenceLevel: "Preclinical",
    fdaStatus: "Investigational"
  },
  {
    id: "s189",
    peptide: "Zinc Thymulin",
    category: "Immune Support",
    title: "Interactions between zinc and thymulin",
    authors: "M Dardenne et al.",
    year: "1994",
    journal: "Met Based Drugs",
    pubmedId: "18476235",
    url: "https://pubmed.ncbi.nlm.nih.gov/18476235/",
    keyFindings: "Serum thymulin activity was decreased as a result of zinc deficiency, and was corrected by in vivo and in vitro zinc supplementation, suggesting that this parameter could be a sensitive indicator of zinc deficiency.",
    evidenceLevel: "Review",
    citations: 21,
    fdaStatus: "Research Only"
  },
  {
    id: "s190",
    peptide: "Zinc Thymulin",
    category: "Immune Support",
    title: "Serum thymulin in human zinc deficiency.",
    authors: "A S Prasad et al.",
    year: "1988",
    journal: "J Clin Invest",
    pubmedId: "313717",
    url: "https://www.jci.org/articles/view/113717",
    keyFindings: "Serum thymulin activity was decreased in mildly zinc-deficient human subjects and was corrected by zinc supplementation. This provides a possible mechanism for the role of zinc on T cell functions.",
    evidenceLevel: "Clinical Trial",
    citations: 435,
    fdaStatus: "Research Only"
  },
  {
    id: "s191",
    peptide: "Zinc Thymulin",
    category: "Immune Support",
    title: "Zinc induces thymulin secretion from human thymic epithelial cells in vitro and augments splenocyte and thymocyte responses in vivo",
    authors: "A R Saha et al.",
    year: "1995",
    journal: "Int J Immunopharmacol",
    pubmedId: "8582784",
    url: "https://pubmed.ncbi.nlm.nih.gov/8582784/",
    keyFindings: "Zinc induces human thymic epithelial cells to secrete zinc-thymulin. Treatment with zinc may have immunotherapeutic relevance, particularly in the aged and stressed organism.",
    evidenceLevel: "In Vitro",
    citations: 124,
    fdaStatus: "Research Only"
  },
  {
    id: "s192",
    peptide: "BPC-157 + TB-500",
    category: "Blend",
    title: "Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain",
    authors: "Lee E, Padgett B",
    year: "2021",
    journal: "Alternative Therapies in Health & Medicine",
    pubmedId: "34324435",
    url: "https://pubmed.ncbi.nlm.nih.gov/34324435/",
    keyFindings: "A retrospective study on 16 patients showed that intra-articular injections of BPC-157, alone or combined with TB4, provided significant pain relief in 87.5% of cases with various types of knee pain.",
    evidenceLevel: "Case Report",
    citations: 37,
    fdaStatus: "Investigational"
  },
  {
    id: "s193",
    peptide: "BPC-157 + TB-500",
    category: "Blend",
    title: "Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing",
    authors: "McGuire FP, Martinez R, Lenz A, et al.",
    year: "2025",
    journal: "Current Reviews in Musculoskeletal Medicine",
    pubmedId: "40789979",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/",
    keyFindings: "This review summarizes the preclinical evidence for BPC-157 in musculoskeletal healing, highlighting its regenerative potential through various molecular pathways. It notes the lack of robust human clinical trials despite its growing popularity.",
    evidenceLevel: "Review",
    citations: 5,
    fdaStatus: "Investigational"
  },
  {
    id: "s194",
    peptide: "BPC-157 + TB-500",
    category: "Blend",
    title: "The Peptide Plastic Surgeon: A Review of Evidence on Regenerative Peptide Supplementation and Potential in Aesthetic Plastic Surgery",
    authors: "Wiegmann AL, Trovato MJ, Gonz\u00e1lez P, et al.",
    year: "2026",
    journal: "Aesthetic Surgery Journal",
    url: "https://academic.oup.com/asj/advance-article-abstract/doi/10.1093/asj/sjag020/8439116",
    keyFindings: "This review examines the evidence for various regenerative peptides, including BPC-157 and TB-500, in the context of aesthetic plastic surgery. It discusses their potential for enhancing healing and tissue regeneration.",
    evidenceLevel: "Review",
    fdaStatus: "Investigational"
  },
  {
    id: "s195",
    peptide: "BPC Wolverine (BPC-157 + TB-500 + GHK-Cu)",
    category: "Blend",
    title: "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration",
    authors: "Chung-Hsun Chang, et al.",
    year: "2011",
    journal: "Journal of Applied Physiology",
    pubmedId: "21030672",
    url: "https://journals.physiology.org/doi/abs/10.1152/japplphysiol.00945.2010",
    keyFindings: "BPC 157 promotes the ex vivo outgrowth of tendon fibroblasts from tendon explants, cell survival under stress, and the in vitro migration of tendon fibroblasts, which is likely mediated by the activation of the FAK-paxillin pathway.",
    evidenceLevel: "Preclinical",
    citations: 90,
    fdaStatus: "Research Only"
  },
  {
    id: "s196",
    peptide: "BPC Wolverine (BPC-157 + TB-500 + GHK-Cu)",
    category: "Blend",
    title: "Thymosin \u03b24: a multi-functional regenerative peptide. Basic properties and clinical applications",
    authors: "Allan L Goldstein, et al.",
    year: "2012",
    journal: "Expert Opinion on Biological Therapy",
    pubmedId: "22074294",
    url: "https://pubmed.ncbi.nlm.nih.gov/22074294/",
    keyFindings: "Thymosin \u03b2(4) is a naturally-occurring peptide that plays a vital role in the repair and regeneration of injured cells and tissues. It protects cells from damage, reduces apoptosis and inflammation, and promotes cell migration and stem cell mobilization to form new blood vessels and regenerate tissue.",
    evidenceLevel: "Review",
    citations: 5,
    fdaStatus: "Investigational"
  },
  {
    id: "s197",
    peptide: "BPC Wolverine (BPC-157 + TB-500 + GHK-Cu)",
    category: "Blend",
    title: "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data",
    authors: "Loren Pickart, Anna Margolina",
    year: "2018",
    journal: "International Journal of Molecular Sciences",
    pubmedId: "29986520",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/",
    keyFindings: "GHK-Cu has multiple biological actions, including stimulating blood vessel and nerve outgrowth, increasing collagen and elastin synthesis, and improving tissue repair in skin, lung, bone, liver, and stomach lining. It also has anti-cancer, anti-inflammatory, and DNA repair actions.",
    evidenceLevel: "Review",
    citations: 198,
    fdaStatus: "Research Only"
  },
  {
    id: "s198",
    peptide: "CJC-1295 + Ipamorelin",
    category: "Growth Hormone",
    title: "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults",
    authors: "Teichman SL, et al.",
    year: "2006",
    journal: "J Clin Endocrinol Metab",
    pubmedId: "16352683",
    url: "https://pubmed.ncbi.nlm.nih.gov/16352683/",
    keyFindings: "Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated. There was evidence of a cumulative effect after multiple doses.",
    evidenceLevel: "Randomized Controlled Trial",
    citations: 119,
    fdaStatus: "Investigational"
  },
  {
    id: "s199",
    peptide: "CJC-1295 + Ipamorelin",
    category: "Growth Hormone",
    title: "Ipamorelin, the first selective growth hormone secretagogue",
    authors: "Raun K, et al.",
    year: "1998",
    journal: "Eur J Endocrinol",
    pubmedId: "9849822",
    url: "https://pubmed.ncbi.nlm.nih.gov/9849822/",
    keyFindings: "Ipamorelin is a potent and selective growth hormone (GH) secretagogue that stimulates GH release via a GHRP-like receptor. It did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation.",
    evidenceLevel: "Preclinical",
    citations: 150,
    fdaStatus: "Investigational"
  },
  {
    id: "s200",
    peptide: "CJC-1295 + Ipamorelin",
    category: "Growth Hormone",
    title: "Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function",
    authors: "Helsinn Therapeutics (U.S.), Inc.",
    year: "2017",
    journal: "ClinicalTrials.gov",
    url: "https://clinicaltrials.gov/study/NCT01280344",
    keyFindings: "This was a phase 2 clinical trial to evaluate the safety and efficacy of ipamorelin for the recovery of gastrointestinal function in patients following small or large bowel resection. The study was completed in 2014.",
    evidenceLevel: "Clinical Trial",
    fdaStatus: "Investigational"
  },
  {
    id: "s201",
    peptide: "Selank + Semax",
    category: "Blend",
    title: "Functional Connectomic Approach to Studying Selank and Semax Effects",
    authors: "Panikratova YR, et al.",
    year: "2020",
    journal: "Doklady Biological Sciences",
    pubmedId: "32342318",
    url: "https://pubmed.ncbi.nlm.nih.gov/32342318/",
    keyFindings: "The study assessed the effects of Selank and Semax on brain connectivity in healthy adults. It found that both peptides have general and specific effects on the functional connectivity between the amygdala and temporal cortex.",
    evidenceLevel: "Clinical Trial",
    citations: 8,
    fdaStatus: "Research Only"
  },
  {
    id: "s202",
    peptide: "Selank + Semax",
    category: "Blend",
    title: "The experimental study of the immunomodulating action of Semax and Selank on the model of \u201asocial\u2019 stress",
    authors: "Yasenyavskaya A.L., et al.",
    year: "2022",
    journal: "European Pharmaceutical Journal",
    url: "https://sciendo.com/document/10.2478/afpuc-2022-0004",
    keyFindings: "This study investigated the immunomodulatory effects of Semax and Selank in a social stress model in animals. The results showed that both peptides act as effective correctors of the immune system, restoring cellular and humoral immunity and neutrophil activity.",
    evidenceLevel: "Preclinical",
    fdaStatus: "Research Only"
  },
  {
    id: "s203",
    peptide: "Selank + Semax",
    category: "Blend",
    title: "Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism",
    authors: "Slominsky PA, et al.",
    year: "2017",
    journal: "Doklady Biological Sciences",
    pubmedId: "28702721",
    url: "https://pubmed.ncbi.nlm.nih.gov/28702721/",
    keyFindings: "In a rat model of Parkinson's disease, Selank was found to decrease anxiety levels, while both Selank and Semax did not affect motor activity. This suggests a potential therapeutic role for Selank in managing non-motor symptoms of Parkinson's.",
    evidenceLevel: "Preclinical",
    citations: 9,
    fdaStatus: "Research Only"
  },
  {
    id: "s204",
    peptide: "Semaglutide + BPC-157",
    category: "Blend",
    title: "Once-Weekly Semaglutide in Adults with Overweight or Obesity",
    authors: "Kushner, R. F., et al.",
    year: "2021",
    journal: "New England Journal of Medicine",
    pubmedId: "33567185",
    url: "https://www.nejm.org/doi/full/10.1056/NEJMoa2032183",
    keyFindings: "In a large-scale clinical trial, once-weekly semaglutide administration led to a substantial and sustained reduction in body weight in adults with overweight or obesity.",
    evidenceLevel: "RCT",
    citations: 1500,
    fdaStatus: "FDA Approved"
  },
  {
    id: "s205",
    peptide: "Semaglutide + BPC-157",
    category: "Blend",
    title: "Anti-inflammatory benefits of semaglutide: State of the art",
    authors: "Ceriello, A., et al.",
    year: "2024",
    journal: "Diabetes, Obesity and Metabolism",
    pubmedId: "38178433",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC10992717/",
    keyFindings: "This review summarizes the evidence for the anti-inflammatory effects of semaglutide, suggesting that these effects may contribute to its cardiovascular benefits.",
    evidenceLevel: "Review",
    citations: 25,
    fdaStatus: "FDA Approved"
  },
  {
    id: "s206",
    peptide: "Semaglutide + BPC-157",
    category: "Blend",
    title: "Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing",
    authors: "McGuire, F. P., et al.",
    year: "2025",
    journal: "Current Reviews in Musculoskeletal Medicine",
    pubmedId: "38448326",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/",
    keyFindings: "This review examines the preclinical evidence for the regenerative properties of BPC-157 in various tissues, while also highlighting the lack of human clinical trials and its ban by the World Anti-Doping Agency.",
    evidenceLevel: "Review",
    citations: 5,
    fdaStatus: "Research Only"
  },
  {
    id: "s207",
    peptide: "Tirzepatide + BPC-157",
    category: "Blend",
    title: "Tirzepatide Once Weekly for the Treatment of Obesity",
    authors: "Jastreboff AM, et al.",
    year: "2022",
    journal: "N Engl J Med",
    pubmedId: "35658024",
    url: "https://www.nejm.org/doi/full/10.1056/NEJMoa2206038",
    keyFindings: "In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight.",
    evidenceLevel: "RCT",
    citations: 1000,
    fdaStatus: "FDA Approved"
  },
  {
    id: "s208",
    peptide: "Tirzepatide + BPC-157",
    category: "Blend",
    title: "Emerging Use of BPC-157 in Orthopaedic Sports Medicine",
    authors: "Vasireddi N, et al.",
    year: "2025",
    journal: "HSS J",
    pubmedId: "40756949",
    url: "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12313605/",
    keyFindings: "BPC-157 helps promote healing by boosting growth factors and reducing inflammation. It has improved outcomes in muscle, tendon, and ligament injuries.",
    evidenceLevel: "Systematic Review",
    citations: 8,
    fdaStatus: "Research Only"
  },
  {
    id: "s209",
    peptide: "Tesamorelin + Ipamorelin",
    category: "Blend",
    title: "Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV",
    authors: "Falutz J, et al.",
    year: "2007",
    journal: "N Engl J Med",
    pubmedId: "18057338",
    url: "https://www.nejm.org/doi/full/10.1056/NEJMoa072375",
    keyFindings: "Daily tesamorelin for 26 weeks decreased visceral fat and improved lipid profiles, effects that might be useful in HIV-infected patients who have treatment-associated central fat accumulation.",
    evidenceLevel: "RCT",
    citations: 241,
    fdaStatus: "FDA Approved"
  },
  {
    id: "s210",
    peptide: "Tesamorelin + Ipamorelin",
    category: "Blend",
    title: "Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.",
    authors: "Falutz J, et al.",
    year: "2010",
    journal: "J Acquir Immune Defic Syndr",
    pubmedId: "20101189",
    url: "https://pubmed.ncbi.nlm.nih.gov/20101189/",
    keyFindings: "Tesamorelin reduces visceral fat by approximately 18% and improves body image distress in HIV-infected patients with central fat accumulation. These changes are achieved without significant side effects or perturbation of glucose.",
    evidenceLevel: "RCT",
    citations: 97,
    fdaStatus: "FDA Approved"
  },
  {
    id: "s211",
    peptide: "Tesamorelin + Ipamorelin",
    category: "Blend",
    title: "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.",
    authors: "Beck DE, et al.",
    year: "2014",
    journal: "Int J Colorectal Dis",
    pubmedId: "25331030",
    url: "https://pubmed.ncbi.nlm.nih.gov/25331030/",
    keyFindings: "This proof-of-concept, phase 2, randomized study evaluated the safety and efficacy of the ghrelin-receptor agonist ipamorelin in the treatment of postoperative ileus following abdominal surgery. Ipamorelin was well tolerated, but there were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses.",
    evidenceLevel: "Clinical Trial, Phase II",
    citations: 31,
    fdaStatus: "Investigational"
  },
  {
    id: "s212",
    peptide: "GLOW Core blend",
    category: "Blend",
    title: "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data",
    authors: "Pickart L, Margolina A",
    year: "2018",
    journal: "Int J Mol Sci",
    pubmedId: "29986520",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/",
    keyFindings: "GHK-Cu stimulates blood vessel and nerve outgrowth, increases collagen, elastin, and glycosaminoglycan synthesis, as well as supports dermal fibroblast function. It improves tissue repair for skin, lung, bone, liver, and stomach lining.",
    evidenceLevel: "Review",
    citations: 132,
    fdaStatus: "Research Only"
  },
  {
    id: "s213",
    peptide: "GLOW Core blend",
    category: "Blend",
    title: "The clinical effect of glutathione on skin color and other related skin conditions: A systematic review",
    authors: "Dilokthornsakul W, Dhippayom T, Dilokthornsakul P",
    year: "2019",
    journal: "J Cosmet Dermatol",
    pubmedId: "30895653",
    url: "https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.12910",
    keyFindings: "This systematic review found that both oral and topical glutathione may brighten skin color in sun-exposed areas, and may also improve skin wrinkles, elasticity, and UV spots.",
    evidenceLevel: "Systematic Review",
    citations: 67,
    fdaStatus: "Supplement"
  },
  {
    id: "s214",
    peptide: "GLOW Core blend",
    category: "Blend",
    title: "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration",
    authors: "Pickart L, Vasquez-Soltero JM, Margolina A",
    year: "2015",
    journal: "Biomed Res Int",
    pubmedId: "26236730",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/",
    keyFindings: "GHK-Cu stimulates both synthesis and breakdown of collagen and glycosaminoglycans, modulates metalloproteinases and their inhibitors, and restores fibroblast vitality. It attracts immune and endothelial cells, accelerating wound healing and improving skin elasticity, density, and firmness.",
    evidenceLevel: "Review",
    citations: 119,
    fdaStatus: "Research Only"
  },
  {
    id: "s215",
    peptide: "GLOW Plus blend",
    category: "Blend",
    title: "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data",
    authors: "Pickart L, et al.",
    year: "2018",
    journal: "International Journal of Molecular Sciences",
    pubmedId: "29986520",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/",
    keyFindings: "GHK-Cu stimulates blood vessel and nerve outgrowth, increases collagen, elastin, and glycosaminoglycan synthesis, and supports the function of dermal fibroblasts. It can tighten loose skin, repair the protective skin barrier, improve skin firmness, elasticity, and clarity, and reduce fine lines and wrinkles.",
    evidenceLevel: "Review",
    citations: 198,
    fdaStatus: "Research Only"
  },
  {
    id: "s216",
    peptide: "GLOW Plus blend",
    category: "Blend",
    title: "Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro",
    authors: "Huang T, et al.",
    year: "2015",
    journal: "Drug Design, Development and Therapy",
    pubmedId: "25995620",
    url: "https://www.dovepress.com/body-protective-compound-157-enhances-alkali-burn-wound-healing-in-viv-peer-reviewed-fulltext-article-DDDT",
    keyFindings: "BPC-157 treatment accelerates wound closure and promotes granulation tissue formation, reepithelialization, dermal remodeling, and collagen deposition in a rat model of alkali burn. It also enhances the proliferation and migration of human umbilical vein endothelial cells (HUVECs) and upregulates the expression of VEGF-a.",
    evidenceLevel: "Preclinical",
    citations: 170,
    fdaStatus: "Research Only"
  },
  {
    id: "s217",
    peptide: "GLOW Plus blend",
    category: "Blend",
    title: "The regenerative peptide thymosin \u03b24 accelerates the rate of dermal healing in preclinical animal models and in patients",
    authors: "Treadwell T, et al.",
    year: "2012",
    journal: "Annals of the New York Academy of Sciences",
    pubmedId: "23050815",
    url: "https://pubmed.ncbi.nlm.nih.gov/23050815/",
    keyFindings: "T\u03b24 accelerated dermal healing of full-thickness punch wounds in various animal models and in two phase 2 clinical trials of stasis and pressure ulcers. It promotes cell migration and stem cell mobilization and differentiation, and by inhibiting inflammation, apoptosis, and infection.",
    evidenceLevel: "Clinical Trial",
    citations: 178,
    fdaStatus: "Investigational"
  },
  {
    id: "s218",
    peptide: "GLOW Ultra Blend",
    category: "Skin/Cosmetic",
    title: "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data",
    authors: "Pickart L, et al.",
    year: "2018",
    journal: "Int J Mol Sci",
    pubmedId: "29986520",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/",
    keyFindings: "GHK-Cu stimulates blood vessel and nerve outgrowth, increases collagen, elastin, and glycosaminoglycan synthesis, and supports dermal fibroblast function. It improves tissue repair in skin, lung, bone, liver, and stomach lining, and possesses anti-cancer, anti-inflammatory, and DNA repair properties.",
    evidenceLevel: "Review",
    citations: 198,
    fdaStatus: "Research Only"
  },
  {
    id: "s219",
    peptide: "GLOW Ultra Blend",
    category: "Skin/Cosmetic",
    title: "Stable Gastric Pentadecapeptide BPC 157 and Wound Healing",
    authors: "Seiwerth S, et al.",
    year: "2021",
    journal: "Front Pharmacol",
    pubmedId: "34267654",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC8275860/",
    keyFindings: "BPC 157 demonstrates potent wound healing capabilities across various tissue types, including skin, by resolving vessel constriction, stabilizing platelet plugs, and counteracting both arterial and venous thrombosis. It also circumvents vessel occlusion in ischemia/reperfusion scenarios.",
    evidenceLevel: "Review",
    citations: 70,
    fdaStatus: "Research Only"
  },
  {
    id: "s220",
    peptide: "GLOW Ultra Blend",
    category: "Skin/Cosmetic",
    title: "The regenerative peptide thymosin \u03b24 accelerates the rate of dermal healing in preclinical animal models and in patients",
    authors: "Treadwell T, et al.",
    year: "2012",
    journal: "Ann N Y Acad Sci",
    pubmedId: "23050815",
    url: "https://pubmed.ncbi.nlm.nih.gov/23050815/",
    keyFindings: "Thymosin \u03b24 (T\u03b24) accelerates dermal healing in various animal models and in human clinical trials of stasis and pressure ulcers. It promotes cell migration, stem cell mobilization, and differentiation, while inhibiting inflammation, apoptosis, and infection.",
    evidenceLevel: "Clinical Trial",
    citations: 41,
    fdaStatus: "Investigational"
  },
  {
    id: "s221",
    peptide: "GLOW Blend Capsules",
    category: "Blend",
    title: "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data",
    authors: "Loren Pickart, Anna Margolina",
    year: "2018",
    journal: "International Journal of Molecular Sciences",
    pubmedId: "29986520",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/",
    keyFindings: "The GHK-Cu peptide has multiple health-positive biological actions. It stimulates blood vessel and nerve outgrowth, increases collagen, elastin, and glycosaminoglycan synthesis, and supports dermal fibroblasts. It also has cell protective actions, including anti-cancer and anti-inflammatory effects.",
    evidenceLevel: "Review",
    citations: 198,
    fdaStatus: "Research Only"
  },
  {
    id: "s222",
    peptide: "GLOW Blend Capsules",
    category: "Blend",
    title: "Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro",
    authors: "Huang T, et al.",
    year: "2015",
    journal: "Drug Design, Development and Therapy",
    pubmedId: "25995620",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC4425239/",
    keyFindings: "BPC-157 treatment accelerates wound healing in a model of alkali burn-induced skin injury. The therapeutic mechanism may be associated with accelerated granulation tissue formation, reepithelialization, dermal remodeling, and collagen deposition through the ERK1/2 signaling pathway.",
    evidenceLevel: "Preclinical",
    citations: 170,
    fdaStatus: "Research Only"
  },
  {
    id: "s223",
    peptide: "GLOW Blend Capsules",
    category: "Blend",
    title: "Thymosin \u03b24 Promotes Dermal Healing",
    authors: "Kleinman HK, Sosne G.",
    year: "2016",
    journal: "Vitamins and Hormones",
    pubmedId: "27450738",
    url: "https://pubmed.ncbi.nlm.nih.gov/27450738/",
    keyFindings: "Thymosin \u03b24 (T\u03b24) increases the rate of dermal healing in various preclinical animal models and accelerated the rate of repair in phase 2 trials with patients having pressure ulcers, stasis ulcers, and epidermolysis bullosa wounds. It is safe and well tolerated.",
    evidenceLevel: "Review",
    citations: 41,
    fdaStatus: "Research Only"
  },
  {
    id: "s224",
    peptide: "KLOW Blend Capsules",
    category: "Blend",
    title: "Stable gastric pentadecapeptide BPC 157 and wound healing",
    authors: "Seiwerth S, et al.",
    year: "2021",
    journal: "Frontiers in Pharmacology",
    pubmedId: "34234714",
    url: "https://www.frontiersin.org/articles/10.3389/fphar.2021.627533/full",
    keyFindings: "This review summarizes the extensive research on BPC 157, a peptide that has demonstrated significant wound healing properties across a wide range of tissues, including skin, muscle, bone, and ligaments. It is noted for its cytoprotective and organo-protective effects, and its favorable safety profile.",
    evidenceLevel: "Review",
    citations: 70,
    fdaStatus: "Research Only"
  },
  {
    id: "s225",
    peptide: "KLOW Blend Capsules",
    category: "Blend",
    title: "Thymosin \u03b24: a multi-functional regenerative peptide. Basic properties and clinical applications",
    authors: "Goldstein AL, Kleinman HK.",
    year: "2012",
    journal: "Expert Opinion on Biological Therapy",
    pubmedId: "22074294",
    url: "https://pubmed.ncbi.nlm.nih.gov/22074294/",
    keyFindings: "Thymosin \u03b24 is a naturally occurring peptide that plays a crucial role in tissue repair and regeneration. It has demonstrated potent anti-inflammatory effects, promotes angiogenesis, and accelerates wound healing in various preclinical and clinical studies.",
    evidenceLevel: "Review",
    citations: 178,
    fdaStatus: "Investigational"
  },
  {
    id: "s226",
    peptide: "KLOW Blend Capsules",
    category: "Blend",
    title: "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data",
    authors: "Pickart L, Margolina A.",
    year: "2018",
    journal: "International Journal of Molecular Sciences",
    pubmedId: "30002320",
    url: "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073405/",
    keyFindings: "This review details the regenerative and protective actions of the GHK-Cu peptide. It has been shown to stimulate collagen and elastin production, improve skin elasticity and firmness, and possesses antioxidant and anti-inflammatory properties, making it a promising agent in skin and hair products.",
    evidenceLevel: "Review",
    citations: 198,
    fdaStatus: "Supplement"
  },
  {
    id: "s227",
    peptide: "Formula M-51",
    category: "Blend",
    title: "Combinations of peptides synergistically activate the regenerative capacity of skin cells in vitro",
    authors: "Michael J Flagler et al.",
    year: "2021",
    journal: "Int J Cosmet Sci",
    pubmedId: "34272744",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC9291327/",
    keyFindings: "Specific peptide combinations (Ac-PPYL + Pal-KTTKS + Nam and Ac-PPYL + Pal-KT) work synergistically to enhance the regenerative capacity of skin cells in vitro. These combinations activate pathways associated with skin repair and rejuvenation, similar to fractional laser treatment.",
    evidenceLevel: "In Vitro",
    citations: 28,
    fdaStatus: "Research Only"
  },
  {
    id: "s228",
    peptide: "Formula M-51",
    category: "Blend",
    title: "Topical Peptide Treatments with Effective Anti-Aging Results",
    authors: "Silke Karin Schagen",
    year: "2017",
    journal: "Cosmetics",
    pubmedId: "317120448",
    url: "https://www.mdpi.com/2079-9284/4/2/16",
    keyFindings: "This review summarizes the data on various cosmeceutical peptides that have been shown to work against skin aging. It discusses different classes of peptides, including signal peptides, carrier peptides, and neurotransmitter inhibitor peptides, and their mechanisms of action.",
    evidenceLevel: "Review",
    citations: 242,
    fdaStatus: "Research Only"
  },
  {
    id: "s229",
    peptide: "Formula M-51",
    category: "Blend",
    title: "Anti-Aging Efficacy of a Multi-Peptides\u2013Silybin Complex: Mechanistic Insights and a 56-Day Clinical Evaluation",
    authors: "H Zhang et al.",
    year: "2025",
    journal: "Cosmetics",
    url: "https://www.mdpi.com/2079-9284/12/5/223",
    keyFindings: "A novel anti-aging cream combining seven bioactive peptides with silybin showed significant improvements in wrinkle area and volume, elasticity, firmness, and dermal density in a 56-day clinical study. The formulation was found to upregulate the expression of collagen and lysyl oxidase (LOX).",
    evidenceLevel: "Clinical Trial",
    fdaStatus: "Research Only"
  },
  {
    id: "s230",
    peptide: "Formula N-5550",
    category: "Cognitive",
    title: "The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease",
    authors: "Wright JW, Harding JW",
    year: "2015",
    journal: "J Alzheimers Dis",
    pubmedId: "25649658",
    url: "https://pubmed.ncbi.nlm.nih.gov/25649658/",
    keyFindings: "Dihexa, an angiotensin-based small molecule, shows promise in facilitating the formation of new functional synaptic connections and augmenting memory consolidation in animal models of AD. It is orally active, penetrates the blood-brain barrier, and may be an effective treatment for Alzheimer's Disease.",
    evidenceLevel: "Review",
    citations: 53,
    fdaStatus: "Investigational"
  },
  {
    id: "s231",
    peptide: "Formula N-5550",
    category: "Cognitive",
    title: "Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue",
    authors: "Rojas JC, Bruchey AK, Gonzalez-Lima F",
    year: "2012",
    journal: "Progress in Neurobiology",
    pubmedId: "22067936",
    url: "https://www.sciencedirect.com/science/article/pii/S0301008211001948",
    keyFindings: "Low doses of methylene blue act as an electron cycler in the mitochondrial electron transport chain, which enhances cell respiration and provides antioxidant effects. These actions improve memory consolidation and offer neuroprotection against mitochondrial dysfunction, making it a promising agent for treating memory impairment and neurodegeneration.",
    evidenceLevel: "Review",
    citations: 236,
    fdaStatus: "Investigational"
  },
  {
    id: "s232",
    peptide: "Formula N-5550",
    category: "Cognitive",
    title: "Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial",
    authors: "Astrup A, et al.",
    year: "2008",
    journal: "The Lancet",
    pubmedId: "19041418",
    url: "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61525-1/fulltext",
    keyFindings: "Tesofensine, a presynaptic inhibitor of noradrenaline, dopamine, and serotonin uptake, was shown to be effective for weight loss in a 24-week trial with obese patients. The 0.5 mg dose produced a mean weight loss of 11.3 kg, significantly more than placebo, with an acceptable side-effect profile.",
    evidenceLevel: "RCT",
    citations: 266,
    fdaStatus: "Investigational"
  },
  {
    id: "s233",
    peptide: "Formula N-259",
    category: "Sleep",
    title: "Apigenin: a natural molecule at the intersection of sleep and aging",
    authors: "Kramer DJ, Johnson AA",
    year: "2024",
    journal: "Frontiers in Nutrition",
    pubmedId: "38425332",
    url: "https://pubmed.ncbi.nlm.nih.gov/38425332/",
    keyFindings: "Apigenin, a natural flavonoid, shows promise in improving sleep quality and has anti-aging properties. It has been shown to improve learning and memory in older mice and reduce tumor proliferation.",
    evidenceLevel: "Review",
    citations: 33,
    fdaStatus: "Supplement"
  },
  {
    id: "s234",
    peptide: "Formula N-259",
    category: "Sleep",
    title: "The effects of L-theanine (Suntheanine) on objective sleep quality in boys with attention deficit hyperactivity disorder (ADHD): a randomized, double-blind, placebo-controlled clinical trial.",
    authors: "Lyon MR, Kapoor MP, Juneja LR",
    year: "2011",
    journal: "Alternative medicine review",
    pubmedId: "22214254",
    url: "https://pubmed.ncbi.nlm.nih.gov/22214254/",
    keyFindings: "L-theanine was shown to be a safe and effective aid for improving some aspects of sleep quality in boys diagnosed with ADHD.",
    evidenceLevel: "RCT",
    citations: 206,
    fdaStatus: "Supplement"
  },
  {
    id: "s235",
    peptide: "Formula N-259",
    category: "Sleep",
    title: "The Effects of Magnesium Supplementation on Subjective Anxiety and Stress-A Systematic Review",
    authors: "Boyle NB, Lawton C, Dye L",
    year: "2017",
    journal: "Nutrients",
    pubmedId: "28445426",
    url: "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452159/",
    keyFindings: "Existing evidence is suggestive of a beneficial effect of Magnesium supplementation on subjective anxiety.",
    evidenceLevel: "Systematic Review",
    citations: 445,
    fdaStatus: "Supplement"
  },
  {
    id: "s236",
    peptide: "Formula N-69",
    category: "Sexual Health",
    title: "Neuro-Cognitive Effects of Acute Tyrosine Administration on Reactive and Proactive Response Inhibition in Healthy Older Adults",
    authors: "Bloemendaal M, et al.",
    year: "2018",
    journal: "eNeuro",
    pubmedId: "30094335",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC6084775/",
    keyFindings: "Tyrosine administration did not significantly alter reactive or proactive inhibition behaviorally across the group, but it did increase fronto-parietal proactive inhibition-related activation. With increasing age, tyrosine had detrimental effects on proactive slowing and decreased fronto-striatal and parietal proactive signals.",
    evidenceLevel: "Clinical Trial",
    citations: 49,
    fdaStatus: "Supplement"
  },
  {
    id: "s237",
    peptide: "Formula N-69",
    category: "Sexual Health",
    title: "Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial",
    authors: "Mills EG, et al.",
    year: "2023",
    journal: "JAMA Network Open",
    pubmedId: "36735285",
    url: "https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2800937",
    keyFindings: "Kisspeptin administration enhanced sexual brain processing, increased penile tumescence, and improved measures of sexual desire and arousal in men with hypoactive sexual desire disorder.",
    evidenceLevel: "RCT",
    citations: 15,
    fdaStatus: "Investigational"
  },
  {
    id: "s238",
    peptide: "Formula N-69",
    category: "Sexual Health",
    title: "PT-141: a melanocortin agonist for the treatment of sexual dysfunction",
    authors: "Molinoff PB, et al.",
    year: "2003",
    journal: "Annals of the New York Academy of Sciences",
    pubmedId: "12851303",
    url: "https://pubmed.ncbi.nlm.nih.gov/12851303/",
    keyFindings: "Administration of PT-141 to men with erectile dysfunction resulted in a rapid, dose-dependent increase in erectile activity, suggesting its promise as a new treatment for sexual dysfunction.",
    evidenceLevel: "Clinical Trial",
    citations: 134,
    fdaStatus: "FDA Approved"
  },
  {
    id: "s239",
    peptide: "Formula N-111 (proprietary peptide blend)",
    category: "Blend",
    title: "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults",
    authors: "Teichman SL, et al.",
    year: "2006",
    journal: "J Clin Endocrinol Metab",
    pubmedId: "16352683",
    url: "https://pubmed.ncbi.nlm.nih.gov/16352683/",
    keyFindings: "A single subcutaneous injection of CJC-1295 in healthy men resulted in a sustained, dose-dependent increase in GH and IGF-1 levels, with effects lasting for at least 7 days. This demonstrates the peptide's potential for less frequent dosing.",
    evidenceLevel: "Clinical Trial",
    citations: 119,
    fdaStatus: "Investigational"
  },
  {
    id: "s240",
    peptide: "Formula N-111 (proprietary peptide blend)",
    category: "Blend",
    title: "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse",
    authors: "Ionescu M, et al.",
    year: "2006",
    journal: "Am J Physiol Endocrinol Metab",
    pubmedId: "16788140",
    url: "https://pubmed.ncbi.nlm.nih.gov/16788140/",
    keyFindings: "In mice genetically engineered to lack GHRH, daily injections of CJC-1295 successfully restored normal growth patterns and body composition. This preclinical study validated the efficacy of CJC-1295 as a potent GHRH analog.",
    evidenceLevel: "Preclinical",
    citations: 55,
    fdaStatus: "Research Only"
  },
  {
    id: "s241",
    peptide: "Formula N-111 (proprietary peptide blend)",
    category: "Blend",
    title: "Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects",
    authors: "Sackmann-Sala L, et al.",
    year: "2009",
    journal: "Growth Horm IGF Res",
    pubmedId: "19394232",
    url: "https://pubmed.ncbi.nlm.nih.gov/19394232/",
    keyFindings: "Administration of CJC-1295 to healthy adult men led to significant changes in their serum protein profiles, indicating a broad physiological response to the activation of the GH/IGF-1 axis. The study identified several proteins that were upregulated, suggesting effects on metabolism and tissue growth.",
    evidenceLevel: "Clinical Trial",
    citations: 46,
    fdaStatus: "Investigational"
  },
  {
    id: "s242",
    peptide: "Formula WL-1175",
    category: "Weight Management",
    title: "Conjugated linoleic acid and L-carnitine combination effects on obesity-related miRNAs in diet-induced obese rats",
    authors: "Nazari M, et al.",
    year: "2023",
    journal: "Obes Res Clin Pract",
    pubmedId: "37634961",
    url: "https://pubmed.ncbi.nlm.nih.gov/37634961/",
    keyFindings: "This study investigated the combined effects of L-Carnitine (LC) and Conjugated Linoleic Acid (CLA) on weight loss and adipose tissue microRNA levels in rats. LC alone significantly decreased weight gain, but the combination with CLA did not show a synergistic effect.",
    evidenceLevel: "Preclinical",
    citations: 1,
    fdaStatus: "Research Only"
  },
  {
    id: "s243",
    peptide: "Formula WL-1175",
    category: "Weight Management",
    title: "The effect of L-carnitine and catechin together with calories restriction on the reduction of body fat and blood lipids",
    authors: "Yen C-H, et al.",
    year: "2025",
    journal: "Journal of Food Bioactives",
    url: "https://www.sciopen.com/article/10.26599/JFB.2025.95030414",
    keyFindings: "This study assessed the effect of L-carnitine and catechin (from green tea) with calorie restriction on body weight and lipid profile. The combination significantly reduced body weight, body fat, and improved the lipid profile in human subjects compared to calorie restriction alone.",
    evidenceLevel: "Clinical Trial",
    fdaStatus: "Supplement"
  },
  {
    id: "s244",
    peptide: "Formula WL-1175",
    category: "Weight Management",
    title: "A review on effects of conjugated linoleic fatty acid (CLA) upon body composition and energetic metabolism",
    authors: "Lehnen TE, et al.",
    year: "2015",
    journal: "J Int Soc Sports Nutr",
    pubmedId: "26388708",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC4574006/",
    keyFindings: "This review summarizes the effects of CLA on body composition and metabolism. While animal studies show promise in reducing body fat, human studies are inconsistent, with some showing modest weight loss and others showing no effect or even adverse effects on glucose and lipid metabolism.",
    evidenceLevel: "Review",
    citations: 277,
    fdaStatus: "Supplement"
  },
  {
    id: "s245",
    peptide: "Formula M-2531",
    category: "Blend",
    title: "MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation",
    authors: "Yuejun Zheng et al.",
    year: "2023",
    journal: "Frontiers in Endocrinology",
    pubmedId: "36761202",
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC9905433/",
    keyFindings: "MOTS-c is a mitochondrial-derived peptide that regulates metabolism and has potential therapeutic applications in aging, cardiovascular disease, insulin resistance, and inflammation.",
    evidenceLevel: "Review",
    citations: 38,
    fdaStatus: "Research Only"
  },
  {
    id: "s246",
    peptide: "Formula M-2531",
    category: "Blend",
    title: "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis",
    authors: "Joseph C. Reynolds et al.",
    year: "2021",
    journal: "Nature Communications",
    pubmedId: "33473142",
    url: "https://www.nature.com/articles/s41467-020-20790-0",
    keyFindings: "MOTS-c treatment enhances physical performance in mice of various ages and improves healthspan by regulating skeletal muscle metabolism and promoting cellular homeostasis.",
    evidenceLevel: "Preclinical",
    citations: 203,
    fdaStatus: "Research Only"
  },
  {
    id: "s247",
    peptide: "Formula M-2531",
    category: "Blend",
    title: "The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance",
    authors: "Changhan Lee et al.",
    year: "2015",
    journal: "Cell Metabolism",
    pubmedId: "25738459",
    url: "https://www.cell.com/cell-metabolism/fulltext/S1550-4131(15)00061-3",
    keyFindings: "MOTS-c treatment in mice prevented age- and diet-dependent insulin resistance and obesity, suggesting its role in regulating metabolic homeostasis.",
    evidenceLevel: "Preclinical",
    citations: 1000,
    fdaStatus: "Research Only"
  },
];
